

2023 Statistical Report



 **Lehigh Valley
Topper Cancer Institute**

Your health deserves a partner.

Lehigh Valley Topper Cancer Institute Mission

We ease our community's cancer burden by preventing cancer, finding cancer early, providing comprehensive diagnostic, consultative, treatment, support and survivorship services, and by educating health care professionals and residents of the communities we serve about advances in cancer care.



WELCOME TO LEHIGH VALLEY TOPPER CANCER INSTITUTE'S 2023 ANNUAL REPORT, which features our statistical data (CY 2022) and insight into the programs, services and innovations in cancer care. Our cancer program that encompasses all campuses in Lehigh Valley Health Network (LVHN) continues to live by our mission to provide outstanding, leading-edge, safe, timely and compassionate care for our patients and communities we serve. We take utmost pride in our dedication, commitment and motivation to provide quality care and outcomes.

Beginning in 2023, Lehigh Valley Topper Cancer Institute transitioned to become an Integrated Network Cancer Program (INCP) with our accreditation by the American College of Surgeons (ACS) Commission on Cancer (CoC). This allowed us to bring together the different campuses of LVHN that would provide standardized, uniform, coordinated and consistent cancer care to our patients from all locations. Integration provides many benefits in enhancing patient outcomes and satisfaction.

Lehigh Valley Topper Cancer Institute offers many and diverse, innovative and leading-edge services in prevention, detection, diagnosis, genetics, patient navigation, nutrition, social and psychological support, rehabilitation, clinical trials, multidisciplinary and coordinated care, surgery, radiation therapy, chemotherapy, immunotherapy, hemophilia care, survivorship, palliative care and hospice support.



John and Dorothy Morgan Cancer Center at Lehigh Valley Hospital-Cedar Crest



LVHN Cancer Center at Lehigh Valley Hospital-Muhlenberg



Cancer Center at Lehigh Valley Hospital-Hazleton



LVHN Cancer Center-Schuylkill



Dale and Frances Hughes Cancer Center at Lehigh Valley Hospital-Pocono



Cancer Center at Lehigh Valley Hospital-Hecktown Oaks



Cancer Center at Lehigh Valley Hospital-Carbon



LVPG Radiation Oncology-Morgan Highway



Cancer Data Management

The cancer data management department of Lehigh Valley Health Network Topper Cancer Institute captures a complete summary of demographics, history, diagnosis, treatment and health status for every cancer patient who presents in our facilities. The data abstracted is stored in a secured cancer registry database, a software information system designed for the collection, management and analysis of data on cancer patients including those diagnosed with benign brain tumors and survivors. The cancer registry is maintained with timely and accurate data to capture cancer incidence, evaluate treatment efficacy and determine survivorship. And, in turn, information is utilized by medical providers, as well as by local, state and national agencies including the Pennsylvania Cancer Registry (PCR), Department of Health and Commission on Cancer's National Cancer Database (NCDB). Cancer Registry data also provides important information to health care providers, researchers and public health officials to enhance monitoring, advance cancer treatments and research and improve cancer screening and prevention programs.

2022 CANCER STATISTICS – LEHIGH VALLEY CANCER INSTITUTE – INTEGRATED NETWORK CANCER PROGRAM (INCP)

The 2023 statistical report is based on calendar year 2022 cancer data in line with the abstracting practice of allowing time to elapse to be able to capture the entire diagnostic, treatment and follow-up information of a cancer case.



All LVHN facilities: Lehigh Valley Hospital (LVH)–Carbon, LVH–Cedar Crest, LVH–Coordinated Health, LVH–Dickson City, LVH–Hazleton, LVH–Hecktown Oaks, LVH–Muhlenberg, LVH–Pocono, LVH–Schuylkill and LVPG–Steamtown

Cancer Staging and Incidence Terminology

Cancer diagnosis, staging, incidence and treatment have a language of their own. Here are some commonly used terms and resources for more information:

AMERICAN JOINT COMMITTEE ON CANCER (AJCC) STAGING

A classification system used for describing the extent of disease progression based on the evaluation of the tumor size/invasion, nodal status and metastasis at the time of diagnosis. AJCC staging is important in determining treatment plans.

ANALYTIC CANCER CASE

Cases for which the facility provided the initial diagnosis of cancer and/or for which the facility contributed to all or part of the first course of treatment.


NATIONAL CANCER DATABASE (NCDB)

The NCDB, a joint project of the American Cancer Society and Commission on Cancer, collects information on cancer cases diagnosed and/or treated at hospitals throughout the country. This patient-anonymous information is used to present scientifically reviewed descriptions of patient diagnosis, treatment and outcome. The most recent data from NCDB for comparison is on cases newly diagnosed in 2022.

RAPID CANCER REPORTING SYSTEM (RCRS)


The CoC's National Cancer Database changed its technology infrastructure with the transition to a new data platform system referred to as RCRS, formerly known as RQRS. RCRS, launched on Sept. 28, 2020, is a web-based data collection and reporting system that analyzes information gathered through the American College of Surgeons' Quality Data Platform vendor, IQVIA. RCRS now serves as the new single-source of data submission for all CoC-accredited hospital registries resulting from the combining of the prior two systems, RQRS and NCDB. Cases submitted to RCRS will include all disease sites from 2007 and going forward. Lehigh Valley Topper Cancer Institute actively participates in the RCRS data collection and reporting program. As a nationwide oncology case repository for real-time and historical data, RCRS enables assessment of hospital-level adherence to quality of cancer care measures for all CoC-accredited programs. Resulting case analysis contributes to a body of evidence-based cancer care knowledge. Based on the evidence, RCRS alerts participants each month to "anticipated care" for their cancer patients. The value in these alerts is to avoid having patients miss out on adjuvant care or therapy that they could receive in addition to their main treatment plan.

CY 2022 TOP FIVE MOST PREVALENT SITES OF CANCER TREATED AT LVHN – INCP




Data source: Lehigh Valley Topper Cancer Institute (INCP) tumor registry: LVH-Cedar Crest, LVH-Muhlenberg, LVH-Hecktown Oaks, LVH-Hazleton, LVH-Pocono, LVH-Dickson City, LVH-Schuylkill, LVPG-Steamtown, LVH-Carbon

Total Annual Analytic Cases, Lehigh Valley Topper Cancer Institute – 10-Year Comparison




Total Annual Analytic Cases by Integrated Network Cancer Program Grouping – 10-Year Comparison



Data source: Lehigh Valley Topper Cancer Institute Tumor Registry; *LVH, Inc.: LVH-Carbon, LVH-Cedar Crest, LVH-Hecktown Oaks, LVH-Muhlenberg, LVPG-Steamtown; LVH-Pocono and LVH-Dickson City; LVH-Hazleton; LVH-Schuylkill

Total Annual Analytic Cases by Facility – 10-Year Comparison





Data source: Lehigh Valley Topper Cancer Institute Tumor Registry


Top Five Most Prevalent Sites of Cancer Treated at Lehigh Valley Health Network Regional Centers, 2022

LVH, INC. (LVH-CEDAR CREST, LVH-MUHLENBERG, LVH-HECKTOWN OAKS, LVH-CARBON, AND LVPG-STEAMTOWN)


LVH-POCONO AND LVH-DICKSON CITY



LVH-HAZLETON




LVH-SCHUYLKILL




Case Classification Based on Patient Migration Patterns

2022 ANALYTIC CASES, INCP



- Diagnosed here and treated elsewhere
- Diagnosed here and treated here
- Diagnosed elsewhere and treated here

Non-Analytic Class of Case Volumes by LVHN Facility, 2022



- LVH, Inc.
- LVH-Pocono and LVH-Dickson City
- LVH-Schuylkill
- LVH-Hazleton

Non-analytic cases represent any of the following scenarios: patients who present at LVH after initial diagnosis and/or treatment elsewhere and patient is referred for consultation, recurrence of cancer or disease progression; pathology specimen only; diagnosed and received all first course of treatment in a staff physician's office; or initially diagnosed at autopsy or death certificate.

Analytic Case Incidence by County of Residence, Five-Year Comparison

Lehigh Valley Cancer Institute provides cancer care for patients in our community and serves as a tertiary referral center. In 2022, encompassing all campuses in LVHN we provided diagnostic care, second-opinion recommendations and treatment to nearly **6,000** patients from **30** Pennsylvania counties. In addition, **96** patients came to our cancer program from communities across the United States.

COUNTY OF RESIDENCE	2018	2019	2020	2021	2022
ADAMS	0	1	0	0	0
BEDFORD	0	0	1	0	0
BERKS	277	278	270	289	347
BRADFORD	3	0	0	0	2
BUCKS	55	50	44	54	53
BUTLER	0	1	0	0	0
CAMBRIA	0	1	0	0	0
CARBON	186	198	151	191	270
CENTRE	0	0	0	1	1
CHESTER	8	7	5	6	2
CLARION	0	0	0	0	1
CLINTON	1	0	0	0	0
COLUMBIA	4	6	4	4	21
CUMBERLAND	1	1	1	2	2
DAUPHIN	1	0	1	1	4
DELAWARE	0	1	2	0	0
GREENE	1	0	0	0	0
INDIANA	0	1	0	0	0
JEFFERSON	2	0	0	0	0
LACKAWANNA	41	42	31	32	206
LANCASTER	0	1	0	0	2
LEBANON	0	1	1	3	0
LEHIGH	1,470	1,453	1,479	1,700	1,708
LUZERNE	153	170	177	211	520
LYCOMING	3	0	0	0	1
MERCER	0	0	0	1	0
MONROE	151	155	144	179	682
MONTGOMERY	71	72	57	78	71
MONTOUR	0	0	0	0	1
NORTHAMPTON	920	949	992	1,113	1,252
NORTHUMBERLAND	2	1	1	2	8
PERRY	0	1	0	0	0
PHILADELPHIA	1	1	1	1	3
PIKE	24	19	11	22	119
POTTER	1	0	0	1	0
SCHUYLKILL	228	269	222	249	577
SNYDER	0	0	1	0	1
SULLIVAN	0	0	2	0	1
SUSQUEHANNA	5	2	2	3	26
UNION	0	1	0	0	0
TIOGA	2	0	0	0	0
VENANGO	1	0	0	0	0
WARREN	0	0	0	1	0
WAYNE	13	11	7	8	55
WYOMING	3	3	3	5	19
YORK	1	0	0	0	1
OUT OF STATE	57	42	70	79	96
TOTAL	3,686	3,738	3,680	4,236	6,052



2022 ANALYTIC CASES BY PRIMARY BODY SITE

LEHIGH VALLEY HOSPITAL (LVH), INC: (LVH-CEDAR CREST, LVH-MUHLENBURG, LVH-HECKTOWN OAKS, LVPG-STEAMTOWN AND LVH-CARBON)

PRIMARY SITE	TOTAL
HEAD AND NECK	151
DIGESTIVE ORGANS	738
ESOPHAGUS	69
STOMACH	63
SMALL INTESTINE	28
COLON	217
RECTOSIGMOID JUNCTION	15
RECTUM	76
ANUS AND ANAL CANAL	21
LIVER AND BILE DUCTS	86
GALLBLADDER	6
OTHER BILIARY TRACT	17
PANCREAS	140
THORAX	502
BRONCHUS AND LUNG	488
THYMUS	1
HEART MEDIASTINUM PLEURA	13
MUSCULOSKELETAL/SOFT TISSUE SITES	42
BLOOD AND BONE MARROW	291
SKIN	178
BREAST	715
FEMALE GENITAL ORGANS	294
VULVA	28
VAGINA	4
CERVIX UTERI	22
CORPUS UTERI	175
UTERUS NOS	4
OVARY	51
OTHER FEMALE GENITAL ORGANS	10

PRIMARY SITE	TOTAL
MALE GENITAL ORGANS	668
PENIS	4
PROSTATE GLAND	646
TESTIS	17
OTHER AND UNSPECIFIED MALE GENITAL ORGANS	1
URINARY TRACT ORGANS	347
KIDNEY	117
KIDNEY, RENAL PELVIS	10
URETER	7
URINARY BLADDER	209
OTHER AND UNSPECIFIED URINARY ORGANS	4
CENTRAL NERVOUS SYSTEM	283
MENINGES	162
BRAIN	81
OTHER NERVOUS SYSTEM	40
ENDOCRINE GLANDS	198
THYROID GLAND	145
ADRENAL GLAND	2
OTHER ENDOCRINE GLANDS	51
OTHER	17
ORBIT, NOS AND OVERLAPPING LESION	2
RETROPERITONEUM AND PERITONEUM	14
OTHER ILL-DEFINED SITES	1
LYMPH NODES	149
UNKNOWN PRIMARY	67
TOTAL	4,640

4,640

Total Analytic Cases LVH, Inc.

2022 ANALYTIC CASES BY PRIMARY BODY SITE

LVH-POCONO AND LVH-DICKSON CITY

PRIMARY SITE	TOTAL
HEAD AND NECK	31
DIGESTIVE ORGANS	102
ESOPHAGUS	7
STOMACH	12
SMALL INTESTINE	2
COLON	36
RECTOSIGMOID JUNCTION	1
RECTUM	10
ANUS AND ANAL CANAL	4
LIVER AND BILE DUCTS	11
OTHER BILIARY TRACT	1
PANCREAS	18
THORAX	95
BRONCHUS AND LUNG	94
HEART MEDIASTINUM PLEURA	1
MUSCULOSKELETAL/SOFT TISSUE SITES	4
BLOOD AND BONE MARROW	46
SKIN	13
BREAST	163
FEMALE GENITAL ORGANS	64
VULVA	1
VAGINA	1
CERVIX UTERI	10
CORPUS UTERI	39
OVARY	11
OTHER FEMALE GENITAL ORGANS	2

PRIMARY SITE	TOTAL
MALE GENITAL ORGANS	71
PENIS	2
PROSTATE GLAND	67
TESTIS	2
URINARY TRACT ORGANS	71
KIDNEY	18
KIDNEY, RENAL PELVIS	1
URETER	4
URINARY BLADDER	47
OTHER AND UNSPECIFIED URINARY ORGANS	1
CENTRAL NERVOUS SYSTEM	34
MENINGES	25
BRAIN	5
OTHER NERVOUS SYSTEM	4
ENDOCRINE GLANDS	34
THYROID GLAND	27
ADRENAL GLAND	1
OTHER ENDOCRINE GLANDS	6
OTHER	3
ORBIT, NOS AND OVERLAPPING LESION	1
RETROPERITONEUM AND PERITONEUM	2
LYMPH NODES	26
UNKNOWN PRIMARY	17
TOTAL	774

774

**Total Analytic Cases LVH-Pocono
and LVH-Dickson City**

2022 ANALYTIC CASES BY PRIMARY BODY SITE

LVH-HAZLETON

PRIMARY SITE	TOTAL
HEAD AND NECK	16
DIGESTIVE ORGANS	71
ESOPHAGUS	7
STOMACH	6
SMALL INTESTINE	2
COLON	21
RECTOSIGMOID JUNCTION	5
RECTUM	5
ANUS AND ANAL CANAL	3
LIVER AND BILE DUCTS	6
OTHER BILIARY TRACT	2
PANCREAS	14
BRONCHUS AND LUNG	55
MUSCULOSKELETAL/SOFT TISSUE SITES	3
BLOOD AND BONE MARROW	20
SKIN	5
BREAST	67
FEMALE GENITAL ORGANS	23
CERVIX UTERI	4
CORPUS UTERI	15
UTERUS NOS	1
OVARY	2
OTHER FEMALE GENITAL ORGANS	1

PRIMARY SITE	TOTAL
MALE GENITAL ORGANS	30
PROSTATE GLAND	29
TESTIS	1
URINARY TRACT ORGANS	23
KIDNEY	5
URINARY BLADDER	18
CENTRAL NERVOUS SYSTEM	28
MENINGES	20
BRAIN	4
OTHER NERVOUS SYSTEM	4
ENDOCRINE GLANDS	12
THYROID GLAND	8
OTHER ENDOCRINE GLANDS	4
RETROPERITONEUM AND PERITONEUM	1
LYMPH NODES	11
UNKNOWN PRIMARY	1
TOTAL	366

366

**Total Analytic Cases
LVH-Hazleton**

2022 ANALYTIC CASES BY PRIMARY BODY SITE

LVH-SCHUYLKILL

PRIMARY SITE	TOTAL
HEAD AND NECK	7
DIGESTIVE ORGANS	63
ESOPHAGUS	8
STOMACH	3
SMALL INTESTINE	1
COLON	22
RECTOSIGMOID JUNCTION	2
RECTUM	12
ANUS AND ANAL CANAL	2
LIVER AND BILE DUCTS	7
GALLBLADDER	1
PANCREAS	5
BRONCHUS AND LUNG	43
MUSCULOSKELETAL/SOFT TISSUE SITES	1
BLOOD AND BONE MARROW	21
SKIN	10
BREAST	35
FEMALE GENITAL ORGANS	24
CERVIX UTERI	4
CORPUS UTERI	16
OVARY	4

PRIMARY SITE	TOTAL
PROSTATE GLAND	8
URINARY TRACT ORGANS	14
KIDNEY	5
KIDNEY, RENAL PELVIS	1
URINARY BLADDER	8
CENTRAL NERVOUS SYSTEM	22
MENINGES	12
BRAIN	5
OTHER NERVOUS SYSTEM	5
ENDOCRINE GLANDS	3
THYROID GLAND	1
OTHER ENDOCRINE GLANDS	2
LYMPH NODES	15
UNKNOWN PRIMARY	6
TOTAL	272



**Total Analytic Cases
LVH-Schuylkill**

2022 Lehigh Valley Topper Cancer Institute Breast Cancer

INCIDENCE OF BREAST CANCER BY AGE AT DIAGNOSIS

AGE AT DIAGNOSIS	0-29	30-39	40-49	50-59	60-69	70-79	80-89	90-103	TOTAL
(N)	5	33	133	202	268	237	87	15	980

BREAST CANCER TREATMENT BY ^AJCC STAGE AT DIAGNOSIS

TREATMENT	STAGE 0	STAGE 1	STAGE 2	STAGE 3	STAGE 4	STAGE UNK	TOTAL*	%
SURGERY + RADIATION + HORMONE	34	172	2	4	0	58	270	28.0%
SURGERY ALONE	41	55	8	1	0	49	154	16.0%
SURGERY + HORMONE THERAPY	14	49	5	0	0	37	105	10.9%
SURGERY + RADIATION THERAPY	20	36	2	2	0	18	78	8.1%
SURGERY + CHEMOTHERAPY	0	32	17	3	1	0	53	5.5%
SURGERY + CHEMOTHERAPY + RADIATION + HORMONE THERAPY	0	28	12	5	2	0	47	4.9%
CHEMOTHERAPY + IMMUNOTHERAPY	0	7	8	7	8	0	30	3.1%
SURGERY + CHEMOTHERAPY + IMMUNOTHERAPY	0	13	7	6	0	1	27	2.8%
SURGERY + CHEMOTHERAPY + RADIATION THERAPY	0	16	6	5	0	0	27	2.8%
SURGERY + CHEMOTHERAPY + RADIATION + IMMUNOTHERAPY	0	9	8	9	0	0	26	2.7%
CHEMOTHERAPY + HORMONE THERAPY	0	1	0	0	21	2	24	2.5%
SURGERY + CHEMOTHERAPY + HORMONE THERAPY	0	15	3	0	1	1	20	2.1%
HORMONE ALONE	6	2	1	2	6	3	20	2.1%
SURGERY + CHEMOTHERAPY + RADIATION + HORMONE + IMMUNOTHERAPY	0	13	0	2	0	0	15	1.6%
CHEMOTHERAPY ALONE	0	1	3	6	1	0	11	1.1%
SURGERY + CHEMOTHERAPY + HORMONE + IMMUNOTHERAPY	0	3	2	0	1	0	6	0.6%
SURGERY + RADIATION + IMMUNOTHERAPY	0	1	0	0	0	1	2	0.2%
RADIATION ALONE	0	0	0	0	2	0	2	0.2%
RADIATION + HORMONE THERAPY + IMMUNOTHERAPY	0	0	0	0	2	0	2	0.2%
CHEMOTHERAPY + HORMONE + IMMUNOTHERAPY	0	1	0	0	0	0	1	0.1%
CHEMOTHERAPY + RADIATION + HORMONE + IMMUNOTHERAPY	0	0	0	0	1	0	1	0.1%
CHEMOTHERAPY + RADIATION + HORMONE THERAPY	0	0	0	0	1	0	1	0.1%
CHEMOTHERAPY + RADIATION + IMMUNOTHERAPY	0	0	0	0	1	0	1	0.1%
SURGERY + RADIATION + HORMONE + IMMUNOTHERAPY	0	1	0	0	0	0	1	0.1%
NO FIRST-COURSE TREATMENT	7	13	3	0	10	6	39	4.0%
TOTAL	122	468	87	52	58	176	963	100%

^Volume data is based on AJCC best stage of disease; Included are 53 cases having post-therapy stage classification.

**15 cases excluded because of histologies not having a stage classification (e.g., phyllodes tumor and LCIS); two cases excluded were diagnosed at autopsy.*

2022 Lehigh Valley Topper Cancer Institute Prostate Cancer

INCIDENCE OF PROSTATE CANCER BY AGE AT DIAGNOSIS

AGE AT DIAGNOSIS	0-29	30-39	40-49	50-59	60-69	70-79	80-89	90-100	TOTAL
(N)	0	0	9	90	312	246	86	7	750

PROSTATE CANCER TREATMENT BY AJCC STAGE AT DIAGNOSIS

TREATMENT	STAGE 1	STAGE 2	STAGE 3	STAGE 4	STAGE UNK	TOTAL	%
RADIATION + HORMONE THERAPY	1	104	42	22	10	179	23.9%
SURGERY ALONE	28	80	34	3	8	153	20.4%
RADIATION ALONE	17	70	7	3	5	102	13.6%
HORMONE ALONE	2	1	6	33	5	47	6.3%
SURGERY + HORMONE THERAPY	1	5	5	8	0	19	2.5%
SURGERY + RADIATION + HORMONE THERAPY	0	6	9	4	0	19	2.5%
SURGERY + RADIATION THERAPY	2	0	2	0	0	4	0.5%
CHEMOTHERAPY + HORMONE THERAPY	0	0	0	4	0	4	0.5%
CHEMOTHERAPY + RADIATION + HORMONE THERAPY	0	0	0	3	0	3	0.4%
CHEMOTHERAPY ALONE	0	0	0	2	0	2	0.3%
SURGERY + CHEMOTHERAPY + RADIATION + HORMONE	0	0	0	2	0	2	0.3%
SURGERY + CHEMOTHERAPY + RADIATION	0	0	1	0	0	1	0.1%
RADIATION + HORMONE THERAPY + IMMUNOTHERAPY	0	0	0	1	0	1	0.1%
OTHER	0	1	0	0	0	1	0.1%
NO FIRST-COURSE TREATMENT	103	62	6	7	35	213	28.4%
TOTAL	154	329	112	92	63	750	100%

Volume data is based on AJCC best stage of disease.

2022 Lehigh Valley Topper Cancer Institute Lung Cancer

INCIDENCE OF LUNG CANCER BY AGE AT DIAGNOSIS: INCP 2022

AGE AT DIAGNOSIS	0-29	30-39	40-49	50-59	60-69	70-79	80-89	90-100	TOTAL
(N)	0	0	11	74	224	247	110	13	679

LUNG CANCER TREATMENT BY ^AJCC STAGE AT DIAGNOSIS

TREATMENT	STAGE 0	STAGE 1	STAGE 2	STAGE 3	STAGE 4	STAGE UNK	STAGE NA	TOTAL	L%
RADIATION ALONE	0	109	10	6	26	1	0	152	22.4%
SURGERY ALONE	4	87	7	4	0	5	0	107	15.8%
CHEMOTHERAPY + RADIATION + IMMUNOTHERAPY	0	0	4	32	48	5	0	89	13.1%
CHEMOTHERAPY + RADIATION THERAPY	0	2	5	34	17	0	0	58	8.6%
CHEMOTHERAPY + IMMUNOTHERAPY	0	0	3	8	34	1	0	46	6.8%
CHEMOTHERAPY ALONE	0	0	0	3	24	0	0	27	4.0%
IMMUNOTHERAPY ALONE	0	3	0	2	8	0	0	13	1.9%
SURGERY + CHEMOTHERAPY	0	3	6	3	0	0	0	12	1.8%
RADIATION + IMMUNOTHERAPY	0	0	0	0	10	0	1	11	1.6%
SURGERY + CHEMOTHERAPY + RADIATION + IMMUNOTHERAPY	0	0	0	5	0	0	0	5	0.7%
SURGERY + CHEMOTHERAPY + IMMUNOTHERAPY	0	0	1	2	0	0	0	3	0.4%
SURGERY + CHEMOTHERAPY + RADIATION THERAPY	0	0	0	2	0	0	1	3	0.4%
CHEMOTHERAPY + HORMONE + IMMUNOTHERAPY	0	0	0	1	1	0	0	2	0.3%
HORMONE ALONE	0	0	0	0	2	0	0	2	0.3%
OTHER	0	0	0	0	2	0	0	2	0.3%
NO FIRST-COURSE TREATMENT	1	22	7	29	81	5	1	146	21.5%
TOTAL	5	226	43	131	253	17	3	678	100%

[^]Volume data is based on AJCC best stage of disease; ^{*}one case excluded, diagnosed at autopsy.

2022 Lehigh Valley Topper Cancer Institute Colon Cancer

INCIDENCE OF COLON CANCER BY AGE AT DIAGNOSIS

AGE AT DIAGNOSIS	0-19	20-29	30-39	40-49	50-59	60-69	70-79	80-89	90-100	TOTAL
(N)	4	3	8	33	52	73	77	61	8	319

COLON CANCER TREATMENT BY ^AJCC STAGE AT DIAGNOSIS

TREATMENT	STAGE 0	STAGE 1	STAGE 2	STAGE 3	STAGE 4	STAGE UNK	TOTAL	%
SURGERY ALONE	28	36	74	24	4	15	181	56.7%
SURGERY + CHEMOTHERAPY	1	1	11	39	13	6	71	22.3%
CHEMOTHERAPY ALONE	0	0	0	1	15	2	18	5.6%
CHEMOTHERAPY + IMMUNOTHERAPY	0	0	0	0	12	1	13	4.1%
SURGERY + CHEMOTHERAPY + IMMUNOTHERAPY	0	0	0	1	3	0	4	1.3%
IMMUNOTHERAPY ALONE	0	0	0	0	3	0	3	0.9%
NO FIRST-COURSE TREATMENT	0	2	2	0	19	6	29	9.1%
TOTAL	29	39	87	65	69	30	319	100%

^Volume data is based on AJCC best stage of disease; included are two cases having post-therapy stage classification.

2022 Lehigh Valley Topper Cancer Institute Rectal Cancer

INCIDENCE OF RECTAL CANCER BY AGE AT DIAGNOSIS

AGE AT DIAGNOSIS	0-29	30-39	40-49	50-59	60-69	70-79	80-89	90-100	TOTAL
(N)	0	2	8	29	32	23	8	1	103

RECTAL CANCER TREATMENT BY AJCC STAGE AT DIAGNOSIS

TREATMENT	STAGE 0	STAGE 1	STAGE 2	STAGE 3	STAGE 4	STAGE UNK	TOTAL	%
SURGERY + CHEMOTHERAPY + RADIATION THERAPY	0	1	2	21	5	1	30	29.1%
SURGERY ALONE	7	7	1	2	0	4	21	20.4%
CHEMOTHERAPY + RADIATION THERAPY	0	1	7	8	1	1	18	17.5%
CHEMOTHERAPY ALONE	0	0	0	2	6	0	8	7.8%
RADIATION ALONE	0	0	0	1	3	0	4	3.9%
CHEMOTHERAPY + IMMUNOTHERAPY	0	0	0	0	3	0	3	2.9%
SURGERY + CHEMOTHERAPY	0	0	0	3	0	0	3	2.9%
SURGERY + IMMUNOTHERAPY	0	0	0	0	1	0	1	1.0%
SURGERY + CHEMOTHERAPY + IMMUNOTHERAPY	0	0	0	0	1	0	1	1.0%
CHEMOTHERAPY + RADIATION + IMMUNOTHERAPY	0	0	0	0	1	0	1	1.0%
NO FIRST-COURSE TREATMENT	0	0	3	0	8	2	13	12.6%
TOTAL	7	9	13	37	29	8	103	100%

^aVolume data is based on AJCC best stage of disease; included are 11 cases having post-therapy stage classification.

2022 Lehigh Valley Topper Cancer Institute Blood and Bone Marrow Cancer

INCIDENCE OF BLOOD AND BONE MARROW CANCER BY AGE AT DIAGNOSIS

AGE AT DIAGNOSIS	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80-89	90-99	TOTAL
(N)	6	9	5	7	15	30	83	132	80	11	378

BLOOD AND BONE MARROW CANCER TREATMENT BY ^AJCC STAGE AT DIAGNOSIS

TREATMENT	STAGE 1	STAGE 2	STAGE 3	STAGE 4	STAGE UNK	STAGE NA	TOTAL	%
CHEMOTHERAPY ALONE	1	3	0	3	2	101	110	29.1%
CHEMOTHERAPY + HORMONE + IMMUNOTHERAPY	4	8	5	0	0	4	21	5.6%
IMMUNOTHERAPY ALONE	2	2	1	2	3	6	16	4.2%
CHEMOTHERAPY + IMMUNOTHERAPY	1	0	0	4	0	8	13	3.4%
OTHER THERAPY	0	0	0	0	0	11	11	2.9%
CHEMOTHERAPY + HORMONE THERAPY	0	3	0	0	0	8	11	2.9%
CHEMOTHERAPY + HORMONE + IMMUNOTHERAPY + TRANSPLANT	0	4	4	0	0	0	8	2.1%
CHEMOTHERAPY + RADIATION THERAPY	0	3	0	0	0	2	5	1.3%
CHEMOTHERAPY + STEM CELL TRANSPLANT	0	0	0	0	0	4	4	1.1%
CHEMOTHERAPY + RADIATION + HORMONE + IMMUNOTHERAPY	0	3	1	0	0	0	4	1.1%
CHEMOTHERAPY + RADIATION + IMMUNOTHERAPY + TRANSPLANT	0	1	2	0	0	0	3	0.8%
CHEMOTHERAPY + RADIATION + HORMONE + IMMUNOTHERAPY + TRANSPLANT	2	1	0	0	0	0	3	0.8%
RADIATION ALONE	0	0	2	0	0	0	2	0.5%
HORMONE + IMMUNOTHERAPY	0	2	0	0	0	0	2	0.5%
SURGERY ALONE	0	0	0	0	0	1	1	0.3%
HORMONE ALONE	0	0	0	0	0	1	1	0.3%
CHEMOTHERAPY + RADIATION + IMMUNOTHERAPY	1	0	0	0	0	0	1	0.3%
CHEMOTHERAPY + IMMUNOTHERAPY + TRANSPLANT	0	0	1	0	0	0	1	0.3%
NO FIRST-COURSE TREATMENT	6	3	0	14	48	90	161	42.6%
TOTAL	17	33	16	23	53	236	378	100%

^aVolume data is based on AJCC best stage of disease.

2022 Lehigh Valley Topper Cancer Institute Urinary Bladder Cancer

INCIDENCE OF URINARY BLADDER CANCER BY AGE AT DIAGNOSIS

AGE AT DIAGNOSIS	0-29	30-39	40-49	50-59	60-69	70-79	80-89	90-103	TOTAL
(N)	1	1	7	20	80	104	58	11	282

URINARY BLADDER CANCER TREATMENT BY ^AJCC STAGE AT DIAGNOSIS

TREATMENT	STAGE 0	STAGE 1	STAGE 2	STAGE 3	STAGE 4	STAGE UNK	TOTAL	%
SURGERY ALONE	69	30	9	5	3	14	130	46.1%
SURGERY + IMMUNOTHERAPY	31	25	0	0	0	4	60	21.3%
SURGERY + CHEMOTHERAPY	14	4	13	3	1	5	40	14.2%
SURGERY + CHEMOTHERAPY + IMMUNOTHERAPY	12	4	2	0	4	1	23	8.2%
SURGERY + CHEMOTHERAPY + RADIATION THERAPY	0	0	11	0	0	1	12	4.3%
SURGERY + RADIATION THERAPY	0	1	2	0	2	0	5	1.8%
SURGERY + CHEMOTHERAPY + RADIATION + IMMUNOTHERAPY	0	0	0	0	2	0	2	0.7%
NO FIRST-COURSE TREATMENT	3	0	1	0	1	5	10	3.5%
TOTAL	129	64	38	8	13	30	282	100%

^Volume data is based on AJCC best stage of disease.

2022 Lehigh Valley Topper Cancer Institute Corpus Uteri Cancer

INCIDENCE OF CORPUS UTERI CANCER BY AGE AT DIAGNOSIS

AGE AT DIAGNOSIS	0-29	30-39	40-49	50-59	60-69	70-79	80-89	90-103	TOTAL
(N)	1	12	12	44	89	55	29	3	245

CORPUS UTERI CANCER TREATMENT BY AJCC STAGE AT DIAGNOSIS

TREATMENT	STAGE 1	STAGE 2	STAGE 3	STAGE 4	STAGE UNK	TOTAL	%
SURGERY ALONE	79	2	4	1	7	93	38.0%
SURGERY + RADIATION THERAPY	55	9	0	0	3	67	27.3%
SURGERY + CHEMOTHERAPY + RADIATION THERAPY	18	4	9	0	0	31	12.7%
SURGERY + CHEMOTHERAPY	1	0	2	9	0	12	4.9%
RADIATION THERAPY ALONE	3	0	0	3	0	6	2.4%
CHEMOTHERAPY ALONE	0	0	1	4	0	5	2.0%
SURGERY + HORMONE	0	0	0	1	1	2	0.8%
SURGERY + CHEMOTHERAPY + IMMUNOTHERAPY	0	2	0	0	0	2	0.8%
CHEMOTHERAPY + RADIATION	0	0	1	1	0	2	0.8%
SURGERY + RADIATION + HORMONE	0	1	0	0	0	1	0.4%
SURGERY + CHEMOTHERAPY + RADIATION + IMMUNOTHERAPY	0	0	1	0	0	1	0.4%
RADIATION + HORMONE	1	0	0	0	0	1	0.4%
NO FIRST-COURSE TREATMENT	6	0	4	9	3	22	9.0%
TOTAL	163	18	22	28	14	245	100%

**Volume data is based on AJCC best stage of disease.*

OUR MOM BEAT
CANCER

#CANCERSURVIVOR 

ssion 12



John and Dorothy Morgan Cancer Center Celebrates 30 Years of Compassionate Care

“In the last three decades our clinicians and support staff have worked tirelessly to predict, prevent and treat cancer at the John and Dorothy Morgan Cancer Center. We provided our neighbors, friends, family members and colleagues access to the latest cancer treatments, technologies and trials, allowing them to receive world-class treatment close to their own homes.”

Since the **John and Dorothy Morgan Cancer Center** opened three decades ago, Lehigh Valley Topper Cancer Institute has treated more than **123,500** cancer patients institute-wide and has expanded to a total of eight locations. Physician in Chief Suresh Nair, MD, has a message for his colleagues and everyone who has supported the Cancer Institute along the way.



Cancer Institute Launches Region's First Stem Cell Transplant and Cellular Therapy Program

HEMATOLOGIST AMIR TOOR, MD, LEADS THE GROUNDBREAKING PROGRAM

Lehigh Valley Topper Cancer Institute has provided state-of-the-art cancer treatments and research opportunities to individuals within their own communities.

While many of the Cancer Institute's patients are able to receive the most advanced therapies for their diagnosis close to home, people who needed hematopoietic cell transplant or cellular immunotherapy have always needed to travel outside of the Lehigh Valley for these treatments. That changed with the development of Lehigh Valley Topper Cancer Institute's Stem Cell Transplant and Cellular Therapy Program.

A wealth of experience



Hematologist Amir Toor, MD, joined Lehigh Valley Topper Cancer Institute in March 2023. He started building the program and educating staff members on the intricacies of these specialized treatments. These leading-edge treatments are lifesaving for many patients with hematologic malignancies, but they are also physically and mentally taxing. Being able to receive these therapies close to home is an absolute advantage for these patients.

Dr. Toor has more than 20 years of experience with autologous and allogeneic transplants. He also has expertise with cellular therapies for hematologic

malignancies, specifically chimeric antigen receptor (CAR) T-cell therapy. He has published extensively on the immunobiology and application of hematopoietic cell transplantation, with nearly 200 scientific abstracts and peer-reviewed publications over the span of his career. His particular interest is in transplantation for multiple myeloma, lymphoma, myelodysplastic syndrome, acute leukemia and myeloproliferative neoplasms. Dr. Toor is a renowned transplant, and he is dedicated to determining the best treatment option for each individual based on their comorbidities and the genomics of their malignancy. He is also heavily involved in researching novel cellular therapies that could lead to better outcomes and quality of life for patients in the near future, and his work in this area will be a major asset to our program.

A phased approach

Initially, the program will offer consultative services (regarding donor selection, transplant eligibility and post-transplant follow-up) for people with a variety of hematologic malignancies as well as transplant procedures in select individuals. Once the program has received accreditation from the Foundation for the Accreditation of Cellular Therapy, it will expand its services to include transplantation for a wide variety of hematologic malignancies and additional cellular therapies (including CAR T-cell therapy).

Lehigh Valley Topper Cancer Institute Clinicians Published in Medical Journals

As a national leader in groundbreaking and state-of-the-art cancer treatments, Lehigh Valley Topper Cancer Institute is involved in many research studies.

Recently, our clinicians' expertise in immunotherapy research was highlighted in two esteemed medical journals – Nature Medicine and The Oncologist.

The Nature Medicine paper highlighted the findings of a trial using viral gene therapy and immunotherapy in recurrent glioblastoma, and The Oncologist paper focused on the results of patients with recurrent,

metastatic platinum-resistant ovarian cancer treated with immunotherapy followed by anti-angiogenic treatment and chemotherapy.

Both of the papers highlighted immunotherapy, with some tweaks, working in cancers that traditionally are not responsive to that treatment modality. The Phase 1/2 glioblastoma trial results are some of the most promising the medical community has seen for that condition, and the ovarian cancer paper highlighted patients experiencing progression-free survival rates that were significantly longer than previously published averages.



Left to right: Christine Kim, MD; Rachel Kinney, DO; Suresh Nair, MD; M. Bijoy Thomas, MD; Martin DelaTorre, DO

New Cancer Center Opens at LVH-Hazleton

Facing a cancer diagnosis is one of the most difficult moments in someone's life as they seek the most advanced lifesaving care. For residents of Greater Hazleton and surrounding counties, cancer treatment options are more accessible than ever with the opening of the Cancer Center at Lehigh Valley Hospital-Hazleton, part of Lehigh Valley Topper Cancer Institute.

This new facility provides access to quality cancer treatment near home, near loved ones and near a patient's support network, something that is critically important in the fight against cancer. This center also gives patients access to all the services and programs of Lehigh Valley Topper Cancer Institute, a member of the Memorial Sloan Kettering Cancer Alliance, which has further enhanced our ability to provide state-of-the-art cancer treatments, technologies and clinical trials.

The 32,000-square-foot, \$20-million cancer center brings the next level of care to our community. It is home to many advanced offerings, facilities and technologies, including:

- A state-of-the-art radiation therapy program offering innovative technologies and treatments
- An expanded infusion suite with private treatment rooms
- Access to Cancer Institute experts
- Expanded telemedicine services

The centerpiece of the new center is a linear accelerator with a computed tomography simulator that can deliver precision stereotactic radiation therapy to treat cancer. This raises the bar for cancer care in LVHN's Northwest Region.

For patients' comfort and relaxation, the center was designed with esthetically pleasing colors and furnishings to aid in treatment and care. The caring and compassionate team provides the best and most appropriate treatment for a variety of cancers such as precancerous blood disease (pre-leukemia), nonmalignant blood diseases, chemotherapy and therapeutic infusions, transfusion services, therapeutic phlebotomies and injections. The team also provides education and emotional support for patients and caregivers, as well as nutritional and financial counseling. A nurse navigator helps guide patients during their care.

A critical need for convenient access to quality cancer care in our region continues to grow. According to a 2020 report from the Pennsylvania Department of Health, cancer is among the top five leading causes of death in Pennsylvania. The new cancer center will support this growing need and more with tumor boards and expanded telehealth capabilities that will allow patients to consult with cancer specialists throughout LVHN without having to travel great distances.





Meet Ana Ignat

Ignat is a strategic leader who inspires excellence and is keenly focused on revenue generation and expense management. She comes to Lehigh Valley Health Network from Columbia University Irving Medical Center in New York City where, since 2018, she served as Administrator, Hematology/Oncology, a division that has more than 65,000 annual visits.

In this role, she partnered with the chief of oncology in the design, coordination and implementation of all administrative and financial aspects of the division's clinical, research, teaching and philanthropic activities. She was involved in Epic design and implementation, oversaw financial management of research projects and directed all aspects of the budget process, staff development, credentialing, fellowship coordination, capital equipment and more.



Ana Ignat, MBA, Senior Vice President of Lehigh Valley Topper Cancer Institute

Lehigh Valley Topper Cancer Institute Welcomes New Senior Vice President

The delivery of high-quality cancer care requires collaboration, dedication and sound leadership. These characteristics are among the reasons Lehigh Valley Topper Cancer Institute is a leader in the delivery of world-class cancer care.

Ana Ignat, MBA, joined Lehigh Valley Topper Cancer Institute in May 2023. Ignat has extensive experience in high-performing academic medical centers and hospitals and a proven record of success managing finance and operations in complex organizations. In her new role, Ignat collaborates with Lehigh Valley Topper Cancer Institute Physician in Chief Suresh Nair, MD, to lead the Cancer Institute's services by growing new sites and relationships, driving exceptional clinical quality and providing an exceptional patient experience.

Lehigh Valley Topper Cancer Institute is where what's next happens because our cancer specialists are constantly evolving cancer care. We provide advanced medical techniques, leading-edge technologies and the latest clinical trials through alliances with innovators such as Memorial Sloan Kettering Cancer Center.

Lehigh Valley Topper Cancer Institute Rates Among the Nation's Best

Becker's Healthcare recognized Lehigh Valley Topper Cancer Institute as one of the top 100 hospitals and health systems for oncology.

Becker's Healthcare also recognized Lehigh Valley Topper Cancer Institute as among the 100 hospitals and health systems with great oncology programs to know for 2023.

Cancer programs that received this recognition earned designations from the National Cancer Institute, provide access to numerous clinical trials and have exceptional safety ratings. The list also features cancer centers with internationally known specialists.

This award shows our community and the country that excellent, leading-edge cancer care is available at Lehigh Valley Topper Cancer Institute.

Groundbreaking treatment options

Because of our commitment to providing leading-edge care, Lehigh Valley Topper Cancer Institute can deliver treatments few other hospitals and health systems in the country offer. In 2024, the Cancer Institute will begin offering groundbreaking cellular therapies and stem cell treatments, and, because of our partnerships, we currently offer patients who qualify access to more than **150** clinical trials.

Specialists also use innovative surgical systems such as Gamma Knife® Icon™ to treat difficult-to-reach tumors of the brain and head. This ultra-precise tool limits radiation dosage to healthy tissue and is designed to be a safer and more precise option for treating cancerous and noncancerous conditions of the brain. Gamma Knife Icon also limits complications and side effects because there are no incisions.

Breast Health Services

LVHN Breast Health Services is an American College of Radiology Accredited Center of Excellence. This quality certification is a testament to the quality and experience of our board-certified radiologists. Lehigh Valley Topper Cancer Institute provides convenient access to breast cancer screenings with 17 locations and the only mobile mammography coach in the region. This service brings breast screenings to women across the region in a state-of-the-art motor coach equipped with leading-edge imaging technology. Screenings performed on the coach are read by Lehigh Valley Topper Cancer Institute physicians.

Leading-edge care in a new location

The Cancer Institute's newest location, the Cancer Center at Lehigh Valley Hospital (LVH)-Hazleton, opened in August 2023. This new location provides access to specialists, groundbreaking treatments and world-class cancer care close to home for patients in Hazleton and surrounding regions.

Infusion services

Specially trained nurses and pharmacists provide patients with a safe experience when they receive chemotherapy, infusion therapy, targeted therapy and antibiotics. Infusion centers also provide blood transfusion services and can administer other medications requiring infusion or injections. Between 2020 and 2022, there were more than **143,000** visits to infusion centers across LVHN.

Member of Memorial Sloan Kettering Cancer Alliance

Lehigh Valley Topper Cancer Institute is one of only three cancer centers in the country participating in the Memorial Sloan Kettering Cancer Alliance, which provides patients with additional lifesaving treatments and clinical trials in their own communities.

Cancer Risk and Genetic Assessment Program

Risk assessment program staff:

6 full-time certified genetic counselors

1 outreach coordinator

2 genetic counseling assistants

1 office coordinator

Additional assistance provided by cancer support services staff



Nicholas Lamparella, DO
Director, Gregory and Lorraine Harper
Cancer Risk and Genetics
Assessment Program



April Gheller, CRNP, Nurse Practitioner
(provides follow-up care at genetics
multidisciplinary clinic with Dr. Lamparella)


Cancer can happen to anyone. But some people face a higher risk for certain cancers because of genetic abnormalities that are passed down in families (hereditary cancer). Cancer genetics experts at Lehigh Valley Topper Cancer Institute help patients and their families learn more about their risk and what we can do to preserve their well-being.

The Gregory and Lorraine Harper Cancer Risk and Genetic Assessment Program of Lehigh Valley Topper Cancer Institute has one of the few programs in the region offering the complete range of cancer genetics services, including cancer risk and genetic assessments. Our genetic counselors provide personalized recommendations to help you know your risk for cancer. For those already diagnosed with cancer, we partner with patients and their physicians regarding treatment decisions.

Cancer genetics services include:

- Genetic counseling: Our board-certified genetic counselors specialize in cancer genetics. We explain the risk for hereditary cancer and help you determine whether genetic testing is right for a patient.
- Cancer risk assessments: Our genetic counselors ask questions about a patient's individual and family health history to determine their risk for hereditary cancer. We explain which cancers they may be at risk for and how likely it is for these cancers to develop.
- Genetic testing: Using a sample of a patient's blood, we check for problems in their genes (mutations) that may cause hereditary cancer.

FY 2023



Genetic counseling appointments are available at Cedar Crest, Muhlenberg, Hecktown Oaks and Pocono, and video genetics follow-up clinics are offered at Cedar Crest and Hecktown Oaks.

Current initiatives:

A genetic counselor is available to meet with patients at the breast multidisciplinary clinic and upper gastrointestinal/hepatobiliary multidisciplinary clinic to offer genetic testing. A blood sample can be collected at the multidisciplinary clinic appointment to expedite genetic testing results that will help determine appropriate treatment.


We have begun to offer video genetic counseling visits to make services more accessible to patients across the entire Cancer Institute service area.

Clinical Trials

Lehigh Valley Topper Cancer Institute is focused on **clinical trials** through the Lehigh Valley Health Network partnership with Memorial Sloan Kettering and the Michigan Cancer Research Consortium NCORP. In collaboration with sites at LVH-Cedar Crest and LVH-Muhlenberg, LVH-Pocono has significantly expanded access to select treatment and minimal-risk clinical trials over the last year.

With the expansion came two new physicians and three advanced practice clinicians (APCs) who accrued patients to four treatment trials, three minimal-risk surgical studies and 19 tissue/blood studies for a total of **26** accruals. LVH-Pocono now has two dedicated research staff members who will continue to expand the number of oncology research studies offered to patients at LVH-Pocono.

TRIALS	ADULTS	PEDS	TOTAL
PHASE 1	2	0	2
PHASE 2	24	0	24
PHASE 3	10	1	11
EXPANDED ACCESS	6	0	6
REGISTRY	207	0	207
REGISTRY/BIOLOGY	0	14	14
TISSUE/BLOOD	196	0	196
SURGERY	1	0	1
TOTAL	446	15	461



Study Spotlight

In early 2023, Lehigh Valley Health Network (LVHN) partnered with Abbvie to bring a novel bispecific T-cell engager (BITE) to refractory lymphoma patients in the outpatient setting through a clinical trial. Administration of BITE therapies typically required inpatient admission; however, this trial allowed patients to receive a subcutaneous injection of epcoritamab in the outpatient infusion center and be monitored in the comfort of their own home rather than in the hospital.

The staff at LVHN had to be vigilant to appropriately monitor and treat the associated cytokine release syndrome side effects, which led to advancements in the quality of care for oncology patients. The success of this study allowed Lehigh Valley Topper Cancer Institute to open additional BITE therapy clinical trials for multiple disease sites.

With the development of the Stem Cell Transplant and Cellular Therapy Program, the oncology research team at LVHN continues to make strides and advancements in cancer treatments and plans to initiate research initiatives in this therapeutic space as well.

Breast Health Services

Breast Health Services at Lehigh Valley Health Network is committed to offering world-class breast care for women of all stages of life. Whatever one's breast needs, we offer access to screening and diagnostic services at many breast health centers across the region.

We use the latest advanced-imaging technologies, such as 3D mammography, to detect breast cancer and other breast conditions in the earliest, most treatable stage. For women who experience breast cancer, you can expect innovative cancer care at Lehigh Valley Topper Cancer Institute.

Exceptional quality

Breast Health Services at LVHN is an American College of Radiology Accredited Center of Excellence. We hold accreditation in many quality programs, which is a testament to the outstanding quality we provide to every woman under our care.

Experience

Our board-certified radiologists exceed the national average for finding cancer at its earliest stage. They read more than twice as many mammograms as the Food and Drug Administration (FDA) requires, a volume that leads to an uncommon level of precision.



Advanced technology

Detecting breast cancer as early as possible is our mission. Tomosynthesis, also known as 3D mammography, makes diagnosing hidden breast cancer possible.

During 3D mammography, an arc of X-ray images is taken of each breast. The images are reconstructed into a three-dimensional image. This allows the radiologist to evaluate the breast layer by layer, helping to distinguish a true mass from overlapping tissue, as well as helping detect smaller lesions that may be hidden on a conventional 2D mammogram.

3D mammography is the only mammogram FDA-approved as superior for women with dense breasts.



Breast surgeons, left to right: Luke Rodriguez, MD, Jacqueline Oxenberg, DO, Krista Bott, MD, Heiwon Chung Whang, MD, Lori Alfonse, DO





Convenience on land and on wheels


You have access to the most advanced breast-screening technology available at LVHN breast health centers across the region. Several locations offer walk-in care.

For even more convenience, our mobile mammography coach provides a convenient way for you to receive a 3D screening mammogram. This is the same imaging technology we use at our hospitals, and it is provided by our outstanding Breast Health Services technicians who have specialized in breast mammography.

World-class care

The Cancer Institute is a Certified Quality Breast Center with the National Quality Measures for Breast Centers™ program administered by the National Consortium of Breast Centers, Inc.

This voluntary program focuses on the tracking and sharing of quality measures such as patient satisfaction and timeliness of imaging care, as well as complication rates. We provide each patient with the highest quality of care through shared learning.



*FY 2023, includes all mammograms, all sites

2023 Cancer Program Goals

Lehigh Valley Topper Cancer Institute's Cancer Committee establishes cancer program goals in compliance with the requirements of our accreditation with the Commission on Cancer. For CY 2023 as an Integrated Network Cancer Program, we developed two goals: the development and implementation of a Stem Cell Transplant and Cellular Therapy Program and the Pluvicto program development and implementation.

The development of a Stem Cell Transplant and Cellular Therapy Program aligns with Lehigh Valley Health Network's goal of providing treatment options for our patients closer to home. The Stem Cell Transplant and Cellular Therapy Program will offer lifesaving treatments to our patients with certain blood disorders or cancers, including access to stem cell transplants.

Establishing the program encompassed many elements including building the necessary infrastructure of the program by developing the core team. Amir Toor, MD, Medical Director, is at the helm with more than 20 years of experience with stem cell transplants and vast expertise with cellular therapies for hematologic malignancies. Jordan Mellinger-Kish, Program Director, handles development and approval of policies and procedures, design and implementation of education programs and training for nursing and other allied health professionals, and coordination and engagement of the different stakeholders internally and externally, as well as construction of the designated spaces for the program.

In January 2024, the Cancer Institute received approval from the Department of Health for the Stem Cell Transplant and Cellular Therapy Program being the first of its kind in the region.

The second goal is the development and implementation of the Pluvicto program. It is a new radioimmunotherapy treatment for metastatic prostate cancer currently approved for patients who have failed chemotherapy. The aim is to establish processes to streamline patient identification for treatment, the referral process, patient education and patient management.

This goal was successfully completed, with all patients being evaluated by a multidisciplinary team at meetings of the genitourinary disease management team. And inclusion checklists and a treatment plan were built in Epic, LVHN's electronic health record system. Additionally, patient education materials were designed and approved. Currently, close to **20** patients have been treated. Treatment is available in our Lehigh Valley Hospital-Cedar Crest location.

Monitoring Concordance with Evidence-Based Guidelines

As part of Lehigh Valley Topper Cancer Institute's accreditation with the Commission on Cancer, each calendar year our cancer liaison physician performs a review and analysis of the diagnostic evaluation and treatment of our cancer patients based on recognized evidence-based national guidelines. **For CY 2023, Dennis Sopka, MD, one of our CLPs, performed a retrospective review of prostate cancer patients.** There were **632** prostate cancer patients who met the criteria for review. Patients' charts were reviewed for diagnostic work-up – physical exam, prostate-specific antigen (PSA) study, biopsy, digital rectal examination (DRE) and genetic testing. Diagnostic imaging studies – confirmation testing of MRI, ultrasound, CT scan and bone scan – also were looked at. Lastly, treatment recommendations of active surveillance, surgery and radiation and use of androgen deprivation therapy as deemed appropriate were evaluated.

Overall, the pre-treatment initial diagnostic evaluation process is concordant with the National Comprehensive Cancer Network (NCCN) guidelines with our patients receiving appropriate work-up. First-course treatments provided to patients were appropriate for the stage of the disease, also in accordance with the evidence-based national guidelines.

LVHN Receives National Award to Continue Lung Screening Program

Lehigh Valley Health Network was recognized by the National Cancer Institute as a sub-awardee of its Anderson Award, providing the network with a grant of more than \$900,000 to continue its pilot preventive lung cancer screening program.

Through this screening program, LVHN identifies eligible screening patients with upcoming primary care visits and offers them early lung cancer screenings. LVHN also sends out educational materials through the mail and conducts telephone outreach. Clinicians and care coordinators will soon be able to use these outreach methods in addition to a patient education video in appointments with study participants.


LVHN started its lung cancer screening program after receiving an Anderson Award in 2018. Since then, LVHN has sustained a screening rate of 20 percent among patients. These efforts are why Lehigh Valley Topper Cancer Institute is recognized by the American College of Radiology as an accredited Lung Cancer Screening Center. LVHN uses the latest screening technologies and trusted techniques to continuously meet the highest standards for lung cancer screening.

Infusion Services

Infusion therapy involves the delivery of fluids, including cancer drugs such as chemotherapy, immunotherapy, targeted therapy and antibiotics, as well as blood transfusion and other medications for infusion or injection. Lehigh Valley Topper Cancer Institute has specially trained nurses and pharmacists who help patients have a safe experience – genuinely caring about restoring patients’ sense of wellness. The team assists in making it easy for patients to receive their infusions on schedules that work for them and does everything to make sure that they receive the care to meet each patient’s unique needs.

One of the major hallmarks for patient satisfaction is the patient’s likelihood to recommend to others the area in which they were treated. A roll-up of scores from all seven outpatient infusion centers resulted in a likelihood-to-recommend score of 92.7 with individual scores ranging from 87.3-94.4. This results in a 79th percentile ranking, according to NRC, the Cancer Institute’s patient-satisfaction vendor.


Lehigh Valley Topper Cancer Institute has seven infusion centers



Figures are for CY 2023

Treatment for Advanced Prostate Cancer Available at Lehigh Valley Topper Cancer Institute

PLUVICTO IS THE FIRST RADIOPHARMACEUTICAL TO TARGET SPECIFIC PROSTATE CANCER CELLS



Pluvicto therapy is a novel treatment that offers fresh hope to certain individuals with advanced prostate cancer. After a much-anticipated launch in 2022, the manufacturer temporarily paused production. Now production has resumed, and the leading-edge treatment is once again offered at Lehigh Valley Topper Cancer Institute.

Candidates for Pluvicto have metastatic castrate-resistant prostate cancer (mCRPC) that is prostate-specific membrane antigen-positive (PSMA+). Their cancer is progressive even after prior treatment with other anti-cancer therapies, including an androgen-receptor pathway inhibitor and a taxane-based chemotherapy regimen.

There is a significant unmet need for more treatment options in this group of patients. About **10** percent to **20** percent of people with existing metastatic prostate cancer will reach the castrate-resistant state within three years, and this state remains lethal despite all the advancements we have made over the past decade.

Pluvicto represents a step toward meeting that need through precision medicine. As the only FDA-approved radiopharmaceutical targeting PSMA+ cancer cells, it has two main components:

- A cell-targeting ligand that binds with very high affinity to PSMA-expressing tumor cells
- A therapeutic radioisotope that delivers radiation treatment directly to these cells

The treatment is given intravenously for up to six cycles spaced six weeks apart. That has proved to be a convenient treatment schedule for most patients.

At the Cancer Institute, medical oncologists identify individuals who may benefit from Pluvicto treatment with the aid of specialized PSMA PET scans. When Pluvicto treatment is indicated, it is administered by the nuclear medicine team.

Increasing survival time

In one large clinical trial, individuals with PSMA+ mCRPC who received Pluvicto plus best-standard-of-care lived a median of four months longer than those who received best-standard-of-care alone (15.3 months versus 11.3 months). In another large trial that compared Pluvicto to second-line chemotherapy, Pluvicto had a higher initial response rate and was better tolerated.

In sum, these two major trials support the use of Pluvicto in patients with PSMA+ mCRPC after a single line of chemotherapy.

Minimizing side effects

Interestingly, PSMA is also expressed in the salivary glands, so people undergoing Pluvicto treatment experience dry mouth. Other possible side effects include fatigue, nausea, decreased appetite, anemia and low platelets. There is also the potential for nephrotoxicity.

Overall, however, Pluvicto therapy tends to be extremely well-tolerated. Clinical trials are now investigating its use in combination with other effective therapies and also in the early stages of disease, which will significantly broaden the range of patients who may benefit from this novel therapeutic.

New Prostate Cancer Treatment Option Available

LVHN OFFERING WORLD-CLASS CARE THROUGH FOCAL ONE® HIGH-INTENSITY FOCUSED ULTRASOUND

Lehigh Valley Health Network is the first in Pennsylvania to offer a noninvasive, state-of-the-art prostate cancer treatment that precisely targets the disease with a low risk of complications or side effects. The Focal One system uses robotic-assisted high-intensity focused ultrasound to attack cancerous growths, while sparing the rest of the organ.

The incidence of prostate cancer grew **3** percent each year from 2014 to 2019, reversing a period of decline, according to urologist Angelo Baccala, MD, Chief, Division of Urology, LVHN. Pennsylvania is in the top five states for prostate cancer, and **288,000** cases are predicted in the U.S. this year. Focal One may be an appropriate treatment option for these individuals, depending on the location and quantity of the cancer.

The Focal One advantage

High-intensity focused ultrasound is a noninvasive and effective option for prostate cancer treatment. It uses an ultrasound probe to scan the prostate and deliver high-intensity sound waves to a targeted area. The probe is inserted into the rectum and does not require an incision. The magnitude of ultrasound energy delivered rapidly raises the temperature at the focal point, causing cell damage and cell death, without damaging healthy tissue and structures outside the targeted area.

It offers a wealth of benefits to people with prostate cancer, including a low risk of side effects such as incontinence or erectile dysfunction, precise robotic targeting of prostate tissue with real-time ultrasound monitoring, and less time away from work and leisure activity. Individuals can typically be discharged shortly after the procedure, which is conducted under general or spinal anesthesia.

Exclusive treatment options

Focal One adds another treatment option but is not expected to become the dominant treatment choice. It is not for everyone. That is why LVHN also offers single-port (one incision) robotic surgery. Individuals who undergo this minimally invasive procedure may be discharged the same day. Single-port prostate surgery is not available at many other health networks in the region. Conversely, some people may only require surveillance and active monitoring. There are better alternatives now that may not even require cutting. Men's urologic issues in general, and prostate issues in particular, are getting a lot more attention today, and that is a good thing.




Radiation Oncology

Lehigh Valley Topper Cancer Institute's radiation oncology is committed to delivering high-quality cancer care through personalized and innovative treatment regimens. We use state-of-the-art equipment to offer advanced treatment techniques, including the Lehigh Valley's only Gamma Knife Icon radiosurgery unit.

Services provided:


- Stereotactic body radiotherapy
- Radiosurgery using a Leksell Gamma Knife Icon
- Real-time tumor tracking with Calypso
- Surface-guided radiotherapy with AlignRT
- High dose rate brachytherapy
- Selective internal radiation therapy using SIR-Spheres
- SpaceOAR hydrogel for prostate treatment
- Personalized 3D-printed treatment services



What's new: standardization of care using Aria

- In recent years, our radiation oncology services have been expanding, resulting in five radiation oncology facilities with four different patient databases for radiation treatment delivery. This was not ideal as it was challenging to ensure all facilities were operating at the same standard of care.
- Throughout CY 2022, we transitioned all sites to a single software platform and database for radiation treatment planning and delivery, named Aria.
- Each transition project included training colleagues on a new platform, transferring patient data between systems and modifying practices to conform to the network standard workflow and documentation.
- Project was completed on Nov. 7, 2022, with the final transition of LVH-Cedar Crest and LVH-Muhlenberg to the Aria platform.
- This project resulted in improved continuity of care for patients receiving radiation therapy, increased quality of care provided network-wide through the implementation of evidence-based clinical templates and increased clinical safety through increased use of checklists and hard stops embedded in the new software.

Volumes:





Radiation Therapy for Skin Cancer Produces Excellent Outcomes

A NONINVASIVE, EFFECTIVE ALTERNATIVE TO SURGERY

Skin cancer is the most common type of cancer, with basal and squamous cell carcinomas accounting for the majority of cases. Individuals are typically referred to dermatologists for a biopsy and treatment, which may involve Mohs surgery or other surgical intervention.

Although these methods are highly effective, there is an equally effective alternative: radiation therapy. Radiation therapy can be a first-line treatment for most nonmelanoma skin cancers. Depending on the size of the lesion, patients can require as little as 1½ to 4 weeks of treatment, with daily or every other day sessions involving less than five minutes of radiation exposure. Oncologic outcomes are similar to surgery, and cosmetic results can be superior.

The treatment is noninvasive. Side effects may include temporary redness or scabbing, but people are usually able to continue their normal routines. In December 2019, the American Society for Radiation Oncology published clinical guidelines for the use of radiation therapy for basal and squamous cell cancers in definitive and adjuvant settings. Similar guidelines also were developed by dermatologists.

Faster time to treatment

Most of the skin cancer patients require post-surgical adjuvant therapy. In many cases, these patients could have been treated with radiation alone.



Excellent outcomes

Radiation might be the treatment of choice for frail or elderly people who do not want to undergo surgery.

Multidisciplinary Clinics and Patient Navigation

The oncology navigation and social work teams have shown significant growth during FY 2022. With the opening of LVH-Hecktown Oaks, navigation and social work services were extended to more patients who have been able to benefit from the knowledge and resources that the teams have to offer. As a result of extending services and an increase in utilization by our physicians and LVPG practices, social work referrals and patient encounters have increased by nearly 50 percent in FY 2022.

Multidisciplinary clinic visits





* FY 2022

Oncology Social Work

Social workers are an integral part of the cancer care team by providing individual counseling and resource navigation and locating services that help with transportation and guide patients through the process. Managing the costs associated with a cancer diagnosis can be overwhelming; our oncology social workers help patients find grant resources and financial assistance based on their diagnosis.

Barriers addressed by social work referrals, FY 2022



* FY 2022

Multidisciplinary Cancer Case Conferences

The cancer data management department (cancer registry) organizes multidisciplinary cancer case conferences, also known as tumor boards. These are conferences involving multidisciplinary teams of physicians and other allied health professionals who discuss and evaluate cancer cases and make treatment decisions and recommendations. This process results in improved clinical decision-making, clinical outcomes and overall patient experience.


Tumor boards convene the multidisciplinary team of physicians and clinicians to engage in robust discussions and collaboration to evaluate and discuss treatment planning for our cancer patients. Aside from identifying treatment recommendations, elements of discussion include clinical and pathologic staging of each cancer case, options and eligibility for genetic testing, clinical research studies and supportive care where applicable.

As Lehigh Valley Topper Cancer Institute transitioned to become an Integrated Network Cancer Program starting in January 2023, the tumor boards have become integrated for all campuses in the health network, except for breast tumor boards which we have for both the southern and northern regions, allowing for enhanced partnership, engagement and shared expertise in providing treatment-planning recommendations and decisions for our patients.

The integration of tumor boards – which are available in hybrid format, virtually and in-person from our Lehigh Valley Hospital–Cedar Crest campus – allowed for increased participation from physicians and colleagues from the different campuses of Lehigh Valley Health Network.

In 2023 we also started to have a dedicated skull base tumor board developed by Ravi Sami, MD, Chief, Division of Otolaryngology-Head and Neck Surgery, Institute for Surgical Excellence, which is primarily focused on tumors that grow along the base of the skull or the cavities that surround the eyes – the orbit and the sinus/nasal tract. These tumors can either be benign or malignant. Additionally, in the last quarter of the year we launched the genomics tumor board, advanced by Renu Bajaj, PhD, FACMG, Director, Cytogenetics and Associate Medical Director, Genomics; Kerry Brown, PhD, FACMG, Genomics, Medical Director, and Elizabeth Dellers, MD, Senior Vice-Chair, Chief Anatomic Pathology, LVHN/HNL Lab Medicine. This is a type of molecular tumor board that is becoming common at academic institutions. This tumor board helps to provide a personalized treatment recommendation for targeted therapies as certain studies and data show improved clinical outcomes for patients when treated based on targeted recommendations.

Site-specific specialty multidisciplinary cancer case conferences:



CY 2023 Statistics





LVH–Muhlenberg Third-Floor Renovations Made

After more than five years of planning and a year of construction, renovations to the third floor of LVH–Muhlenberg were completed in June 2023.

The renovated space, which was home to LVHN’s pediatric hematology oncology program before it relocated to LVH–Cedar Crest in 2017, is now home to the network’s Hemophilia Treatment Center (HTC) and the Cancer Center at LVH–Muhlenberg’s Cancer Risk and Genetic Assessment Program, SurvivorPLACE and multidisciplinary clinics.

The renovations included updating three existing exam rooms, adding three exam rooms, creating additional office and drop-in spaces for clinicians, and adding a waiting room, multipurpose room (for care team meetings) and phlebotomy space. The adjacent suite that is home to LVPG Hematology Oncology–Muhlenberg, LVPG Surgical Oncology–Muhlenberg and LVPG Gynecologic Oncology–Muhlenberg underwent a renovation of its check-in station and waiting room at the same time.

The relocation of the network’s HTC and the Cancer Center at LVH–Muhlenberg’s Cancer Risk and Genetic Assessment Program, SurvivorPLACE and multidisciplinary clinics was crucial, as these practices have grown exponentially over the last five years and needed additional space to accommodate patients and clinicians. Since the doors to the new suite opened on June 14, patient wait times have decreased and clinicians who travel between campuses have had access to a designated workspace.

Cancer Rehabilitation Services

Cancer rehabilitation programs can improve function, reduce pain and improve the overall well-being of patients experiencing the challenges of a cancer-related diagnosis. LVHN Rehabilitation Services offers comprehensive care to patients in our communities throughout their cancer journey.

Many survivors of cancer experience lasting, adverse effects caused by either their disease or its treatment. Therapy interventions often can reverse or improve the impairments found in both new and existing patients with a cancer diagnosis and improve their ability to carry out daily tasks and participate in life situations. Patients who can be considered for rehabilitation referrals are those with lymphedema, cancer-related fatigue, range-of-motion deficits, functional strength and flexibility deficits, endurance deficits, swallowing deficits, memory loss/processing deficits and home-management deficits. LVHN Rehabilitation Services can help a cancer patient overcome obstacles related to surgery or side effects from cancer treatment. The rehabilitation team is always committed to pursuing the goal of helping patients improve their daily functions and quality of life.


The rehabilitation team consists of board-certified clinical specialists, including physical therapists, occupational therapists, speech therapists and audiologists, who are available to treat a wide variety of conditions. Additionally, rehabilitation services are available for inpatients and outpatients. For inpatient services, therapy is available seven days a week, 365 days a year, and the order response is within 48 hours.

Inpatient oncology rehabilitation services under LVH Inc. are provided at LVH–Cedar Crest Inpatient Rehabilitation Center (IRC) on the 5K inpatient oncology unit and at Muhlenberg IRC on the 5T medical-surgical unit. Additionally, Rehabilitation Services provides consults at SurvivorPLACE, LVH–Cedar Crest and LVH–Muhlenberg. Inpatient oncology rehabilitation is also available within the IRC LVH–Pocono, Gunderson IRC at LVH–Hazleton and Stine IRC at LVH–Schuylkill. The inpatient rehabilitation team is developing support programs for patients undergoing transformative treatment through the Cancer Institute Stem Cell Transplant and Cellular Therapy Program.

Outpatient Rehabilitation Services has expanded to **54** convenient locations throughout the entire Lehigh Valley Health Network service area. Rehabilitation protocols have been established for cancer-related fatigue, osteoporosis and other musculoskeletal conditions, which can be treated at all physical therapy locations. Therapy for patients with lymphedema, breast cancer, cognitive impairment, speech impairment and audiologic deficits are available at regional outpatient offices.

Oncology referrals to rehabilitation

CY 2023



OACIS/Palliative Medicine

OPTIMIZING ADVANCED COMPLEX ILLNESS SUPPORT

Palliative care services

Palliative care is specialized medical care for people living with a serious illness. This type of care is focused on providing relief from the symptoms and stress of the illness. The goal is to improve quality of life for both the patient and the family.

Palliative care is provided by a specially trained team of doctors, nurses and other specialists who work together with a patient's other doctors to provide an extra layer of support. Palliative care is based on the needs of the patient, not on the patient's prognosis. It is appropriate at any age and at any stage in a serious illness, and it can be provided along with curative treatment.

OACIS/Palliative Medicine can assist with:

- Medical collaboration and management across the care continuum
- Clarifying goals of care and treatment
- Advance care planning
- Self-management goals
- Complex-symptom management
- Complex communication
- Preventive care planning
- Communication and collaboration with oncologist and primary care physicians
- Exploring psychosocial and spiritual needs


Our services are provided in the hospital setting, the office or at home. We offer both in-person and telemedicine options to our patients. We are there to help coordinate with your physician and members of your health care team to determine the kind of care you want.

OACIS/Palliative Medicine clinical branches

- **OACIS home-based practice**
 - In-person and telemedicine
 - Telemedicine to selected skilled nursing facility
 - Interdisciplinary team: nurse practitioners, social workers, clinical support staff
- **OACIS supportive care office-based practice**
 - Cedar Crest-1250
 - Health Center at Palmer Township
 - Telemedicine at LVPG Radiation Oncology-Morgan Highway
 - Interdisciplinary team: physicians, nurse practitioners, social workers, clinical support staff
- **Inpatient palliative medicine consult service**
 - In-person consults at Cedar Crest and Muhlenberg
 - Telemedicine consults at Schuylkill, Hazleton, Pocono, Hecktown Oaks, Carbon, Dickson City and transitional skilled unit (TSU)
 - Interdisciplinary team: physicians, nurse practitioners, social workers, counselor and clinical coordinator

Palliative Care and Oncology (Outpatient)

CY 2023: 295 referrals with 63 percent conversion rate



Financial Coordination

Lehigh Valley Topper Cancer Institute's Financial Coordination Services provides free assistance to our patients as they go through their cancer journey. Our financial coordinators are happy to meet with our patients and their families to help ease their concerns and work with them. They assist on questions about health insurance coverage, medication costs and medical bills. Financial Coordination Services provides the following services at no cost to our patients:

- Assist patients to get the most out of their insurance coverage and minimize potential out-of-pocket costs.
- Explain medical bills and out-of-pocket costs.
- Explore financial assistance options to cover medication costs.
- Help connect patients with financial aid opportunities through cancer support agencies.

FISCAL YEARS	ORAL MEDICATIONS ASSISTANCE	TOTAL NUMBER OF PATIENTS PROVIDED ASSISTANCE FOR ORAL MEDICATIONS	FAP* PATIENTS ASSISTED	PATHS PATIENTS REFERRED
2023	\$39,943,609	462	434	70
2022	\$21,700,196	318	513	83
2021	\$17,559,634	311	626	122
2020	\$13,188,581	344	562	144
2019	\$7,805,256	299	616	130
2018	\$5,114,294	296	615	214
2017	\$5,419,690	176	577	220
2016	\$4,380,076	155	590	223
2015	\$3,058,370	109	655	221
2014	\$3,388,240	152	725	237

*Financial Assistance Patients

2023 Lehigh Valley Topper Cancer Institute Grants and Funds

Lehigh Valley Topper Cancer Institute recognizes that some of our patients encounter **barriers and challenges** as they go through their cancer journey. The Cancer Institute provides assistance to our patients through both internal and external grants and funds that are available.

FUND/GRANT	AMOUNT	NUMBER OF PATIENTS
PRAGER FUND	\$109,498.94	411
COURTNEY FUND	\$3,967.07	15
W5K FALL BACK GRANT	\$1,630.56	10
W5K TRANSPORTATION GRANT	\$2,392.69	69
DOREEN MIRAMS FUND	\$300.00	2
WOMEN TO WOMEN FUND	\$2,831.76	12
SUZANNE ZALE BUCK FUND	\$1,458.99	6
HOPE FOR STRENGTH FUND	\$1,617.18	9
BREATH FOR LIFE FUND	\$2,842.22	12
HAZLETON PATIENT ASSISTANCE FUND	\$765.34	5
HOWARD CANFIELD FUND	\$307.74	2
POCONO CANCER PATIENT ASSISTANCE FUND	\$206.10	1
TOTAL INPATIENTS IMPACTED		554
TOTAL FINANCIAL ASSISTANCE	\$127,818.59	

M. Bijoy Thomas, MD, Surpasses 3,500 Robotic Surgeries

DR. THOMAS IS AMONG THE HIGHEST-VOLUME PERFORMERS IN HIS SPECIALTY

M. Bijoy Thomas, MD, Chief, Gynecologic Oncology, at Lehigh Valley Topper Cancer Institute, celebrated with his team for completing more than 3,500 robotic surgery cases in his career. He ranks among the highest-volume performers in his specialty and at Lehigh Valley Health Network.



New Surgeon Specializes in Minimally Invasive Colorectal Surgery



Bogdan Protyniak, MD, a fellowship-trained colorectal surgeon, is a strong proponent for robotic and other minimally invasive techniques. He can do almost all colon resection or rectal prolapse surgeries this way. Compared to open surgery, this means less pain, fewer complications and a faster recovery.

Dr. Protyniak came to Lehigh Valley Physician Group (LVPG) Colon Rectal Surgery-Pocono and Lehigh Valley Hospital-Pocono in March.

Prior to that, he was at Geisinger for six years, where he rose to become Division Chief of Colorectal Surgery. Since 2016, Dr. Protyniak has lived in Stroudsburg, so he welcomed the opportunity to bring his practice closer to home.

Colon, rectal and anal surgery

Dr. Protyniak has expertise in state-of-the-art robotic and laparoscopic procedures. He treats the gamut of colorectal pathology, including:

- Colon and rectal cancer
- Diverticulitis
- Inflammatory bowel disease (Crohn's disease and ulcerative colitis)

In addition, he treats benign anorectal conditions, such as:

- Hemorrhoids
- Anal fistula and fissures

Individuals undergoing surgery want to get back to their lives and their loved ones as quickly as possible afterward. His use of up-to-date, minimally invasive techniques leads to shorter hospital stays – about two days, on average. One of his near-term goals is to implement a protocol for same-day discharge in select cases.

Dedication, in and out of the operating room

Dr. Protyniak emphasizes the importance of partnering with the individuals he treats. He believes above all in shared decision-making with a focus on honoring his patients' autonomy and working together to identify the best treatment for them.

Collaboration with other members of the health care team is crucial as well. This helps ensure that individuals are aware of all their treatment options, both surgical and nonsurgical.

Dr. Protyniak cites rectal cancer as a condition that specifically benefits from a multidisciplinary team approach. Surgery is typically the mainstay of treatment for rectal cancer. However, for specific individuals, recent research shows the utility of a combination of radiation therapy and chemotherapy alone, thus preserving the rectum and avoiding potential colostomy.

Oncology Nutrition Counseling


Lehigh Valley Topper Cancer Institute offers patients access to registered dietitian nutritionists (RDNs) who are uniquely trained to assist patients and their families in managing treatment-related nutrition concerns. RDNs can address patient needs and goals as well as provide strategies to achieve them before, during and after treatment.

Our RDNs provide screening assessment for risk and diagnosis of malnutrition, nutrition-related problems and obesity, as well as offer medical nutrition therapy, nutrition counseling, nutrition education and management, and coordination of enteral and parenteral nutrition.

They also offer their expertise to community outreach programs through presentations and participation in health fairs for survivorship, health promotion and disease prevention.

In March 2023, they held a Cancer Institute-wide food drive to address food insecurity among cancer patients. About 690 pounds of food were collected at all sites from staff and the community and then distributed to 72 patients who expressed financial difficulty in obtaining adequate access to health food.

Total volumes CY 2023 – for entire program (all sites)





Inpatient Cancer Unit

LEHIGH VALLEY TOPPER CANCER INSTITUTE'S INPATIENT UNIT HAS 22 PRIVATE ROOMS DESIGNED WITH PATIENT SAFETY AND COMFORT IN MIND.

This unit is located on the fifth floor of the Kasych Family Pavilion. In addition to private rooms, the unit offers numerous amenities to ensure that patients have a comfortable place to get well and families have the space they need to support their loved one while they are in the hospital.

Some amenities include

- All rooms have 55-inch TVs with Bluetooth compatibility so that patients can watch Netflix, movies, etc. by using their own cell phones or laptop computer.
- Smart beds are equipped with chargers for personal electronic devices.
- The beds have a modern built-in headboard against the wall to create a more “homelike atmosphere.” Each patient room includes a magnetic board for patients to post personal items (cards, pictures, inspirational quotes, etc.).
- Each of the private rooms protect patients from outside germs with positive pressure and HEPA filters in the ceiling. In addition, six rooms have positive pressure to protect the patient and negative pressure to protect both staff and other patients from any aerosolized infections.
- Other room features include a computer workstation, access to a private bathroom, showers with a foldable chair attached to the wall to offer additional safety and comfort for the patient, and a ceiling lift. One patient room is also lead lined for patients receiving radiation treatment.
- A meditation room for patient and colleague use is also available. The meditation room offers comfortable seating, dimmable lighting, aromatherapy, white noise and a small TV for guided meditation.

All finishes in the room can be scrubbed to achieve high levels of cleanliness and infection prevention.

Addressing Barriers to Care

Lehigh Valley Topper Cancer Institute supports its patients in many ways.

In 2023, the Cancer Institute launched a food drive initiative to help patients address their food insecurity concerns. We hosted a food drive across all campuses of the Cancer Institute. Collection boxes were placed in different locations within LVHN, and nonperishable food items were donated by colleagues and patients. Our registered dietitians assembled a list of nutritious food-item suggestions focusing on our cancer patients' needs.

Care packages were put together and distributed by both our social workers and registered dietitians to our patients. There was a total of **115** bags/food care packages which were shared with patients in need. This was a successful drive which was very well-received and appreciated. This project truly embodies the Cancer Institute's goal to provide compassion and caring to our patients in different ways.



Join Lehigh Valley Topper Cancer Institute in supporting low-income cancer patients with food donations. All nonperishable canned and boxed foods will be accepted. **Please do not donate any items that are expired or packaged in glass.**

Donations will be accepted from March 1 through March 29. Care packages will be distributed to patients throughout the month of April.

Donation Suggestions

- Canned meats, including tuna, chicken and salmon
- Canned beans
- Nut butters (peanut butter, almond butter)
- Canned fruits and vegetables
- Fruit cups
- Dry or microwavable rice
- Dry or microwavable pasta
- Canned soup
- Powdered milk
- Dry cereals, including oatmeal, cold cereal and granola
- Snacks, including granola bars, fruit pouches, nuts and jerky



Questions?

Contact Janine Gilboy at 484-884-3465 or email Janine.Gilboy@lvhn.org.




Collection Box Locations

- LVH-Cedar Crest, John and Dorothy Morgan Cancer Center, lobbies
- LVH-Muhlenberg, Infusion and Radiation Oncology lobby and LVPG Hematology Oncology, third floor, Suite 300
- LVH-Hecktown Oaks, Cancer Center lobby
- LVH-Pocono, Main Hospital Cafeteria and Radiation therapy break room at the Dale and Frances Hughes Cancer Center
- LVH-Schuylkill, Cancer Center, third floor
- LVH-Hazleton, Cancer Center lobby
- LVPG Radiation Oncology, 5 Morgan Highway, Suite 7
- LVH-Carbon, Diagnostic Care Center registration area, Infusion department and LVPG staff lounge
- LVHN-Mack Boulevard, cafeteria



Community Outreach 2023

COMMUNITY SCREENING EVENTS



Oral cancer screenings on April 3 (LVH–Muhlenberg), April 17 (LVH–17th Street) and April 24 (LVH–Hecktown Oaks).

A total of **81** people were screened for oral cancer by LVHN dentists and dental residents.

Skin cancer screenings on May 3 (LVH–Cedar Crest), May 16 (LVH–Muhlenberg) and Sept. 27 (LVH–Schuylkill).

A total of **144** people were screened for skin cancer by dermatologists from Advanced Dermatology Associates and Zaladonis Dermatology Associates.

Breast cancer screenings on Aug. 11 at LVHN–Station Circle in Hazleton and on Oct. 19 at Health Center at West End in Brodheadsville.

A total of **26** people were screened between both events on our mobile mammography coach.

PREVENTION EVENTS

Colorectal Cancer Prevention and Awareness



March 29, at LVH–Cedar Crest and offered virtually on Webex.

31 in attendance and event recording is posted to the LVHN event videos page.

Clinicians from Lehigh Valley Topper Cancer Institute, Colon Rectal Surgery Associates and Eastern PA

Gastroenterology and Liver Specialists shared valuable information on screening updates, risk factors and prevention strategies. A Q&A panel with the physicians followed these presentations.

Skin Cancer Prevention and Awareness

Aug. 7, at the Cancer Center at LVH–Hazleton ribbon-cutting event.

Approximately **100** in attendance.

Included education and resources from Cancer Institute nurse navigators and dietitians on sun protection for adults and children, nutrition, facts about melanoma, and how to spot skin cancer.

Skin Cancer Prevention and Awareness

Aug. 9, at Hometown Farmers Market in Tamaqua.

82 in attendance.

Included education and resources from Cancer Institute nurse navigators on sun protection for adults and children, nutrition, facts about melanoma, and how to spot skin cancer.

PINK OUT AT THE PROMENADE



Oct. 12, at The Promenade Shops at Saucon Valley.

225 in attendance.

Lehigh Valley Topper Cancer Institute physicians and other LVHN care team members shared important new information relating to breast health. Attendees had the opportunity to visit various resource tables including topics on nutrition, genetic counseling, cardio-oncology, Breast Health Services and clinical trials, as well as listen to our physicians speak on exciting updates in their specialties. The mobile mammography coach was on site to offer tours and schedule mammograms.

PINK LIGHT WALK

Oct. 5, at Dale and Frances Hughes Cancer Center at LVH–Pocono and East Stroudsburg University.

500 in attendance.

Lehigh Valley Topper Cancer Institute partnered with East Stroudsburg University (ESU) for the 23rd annual Pink Light Walk for breast cancer prevention and awareness. Attendees started at ESU for an information fair with resources provided by Cancer Institute departments including genetic counseling, nutrition services and Breast Health Services. Participants then walked from ESU to the Hughes Cancer Center to stand together and highlight the importance of breast cancer screening and prevention.

Survivorship Events

ADVANCES IN KIDNEY CANCER CARE



May 18, at Lehigh Country Club, Allentown

113 in attendance and event recording is posted to the LVHN event videos page.

Clinicians from Lehigh Valley Topper Cancer Institute, National Cancer Institute and Kidney Care Specialists, LLC provided valuable updates in kidney cancer care during this celebration of survivorship. Updates in immunotherapy, how to care for your sole kidney and ways to become involved with kidney cancer advocacy were shared. This annual event is sponsored by the Andy Derr Foundation for Kidney Cancer Research.

ADVANCES IN MELANOMA CANCER CARE



May 11, at Lehigh Country Club, Allentown

147 in attendance and event recording is posted to the LVHN event videos page.

Clinicians from Lehigh Valley Topper Cancer Institute and Advanced Dermatology Associates along with a dietitian from Cancer Institute nutrition services provided valuable updates in melanoma cancer care during this celebration of survivorship. Program topics included detecting and preventing skin cancer, T-Vec treatment for advanced melanoma, and foods to fight melanoma.

SURVIVOR NIGHT AT THE IRONPIGS



June 14, 2023, at Coca-Cola Park, Allentown

Approximately 385 cancer survivors and caregivers attended our annual survivorship celebration at the Lehigh Valley IronPigs. Survivors had the opportunity to socialize with one another while enjoying a night out at the ballpark with refreshments and a giveaway.

Patient and Family Advisory Council

The Patient Family Advisory Council at Lehigh Valley Topper Cancer Institute maintains a high-quality patient and family centered care approach. The council consists of institute employees as well as patients and family members. Members of the council collaborate with institute leadership in policy and program development, implementation and evaluation. They are also assistive in health care facility design. In 2022, the Patient Family Advisory Council played an integral role in developing a comprehensive Cancer Patient Guide. This guide was developed to provide helpful information and answer common questions that may cause stress or anxiety.





Lehigh Valley Reilly Children's Hospital

Pediatric cancer is a complex disease, but cancer treatment options are always advancing. Experts at Lehigh Valley Reilly Children's Hospital are here to help. Our team has decades of combined experience treating a wide range of pediatric cancers with excellent results.

When you choose Children's Hospital for cancer care, your child will benefit from our:

World-class treatments

Our pediatric hematology oncology program is part of the Children's Oncology Group (COG), the largest international consortium of pediatric cancer hospitals and clinicians. This association means that we care for patients using the same protocols that the world's foremost cancer centers follow.

Pediatric expertise

Lehigh Valley Reilly Children's Hospital is the region's only institutional member of the Children's Hospital Association. It is also home to the area's only board-certified pediatric specialists in cancer care and other specialties. Our entire team of experts in more than **30** pediatric subspecialties has a passion for providing the highest-quality care for our smallest patients. All of our experts are available to assist in the care of patients with cancer.

Team approach

When you come to Lehigh Valley Reilly Children's Hospital for cancer care, multiple specialists will weigh in on your child's care. This approach helps ensure a treatment plan is tailored to your child's needs. Your care team may include:

Pediatric hematologist oncologist – This doctor specializes in treating blood disorders and cancer in children. Our doctors are fellowship-trained in pediatric hematology oncology.

Pediatric surgeon – This doctor is skilled in surgery and cares for children who may have surgical needs as part of their cancer care. Our pediatric surgeons are fellowship-trained in pediatric surgery specialties.

Pediatric oncology-certified nurses – Many of our registered nurses have earned specialty certification in pediatric hematology oncology and are knowledgeable, compassionate partners in your child's medical care.

Radiation oncologist – This doctor specializes in using radiation to treat cancer.

Pediatric anesthesiologist – This doctor administers medicine during surgery to help infants, children and adolescents relax and fall asleep. Our pediatric anesthesiologists are all fellowship-trained in the use of anesthesia with young patients and are the only team of pediatric anesthesiologists in the area.



Pediatric radiologist – This doctor uses a variety of imaging technologies, such as X-ray, CT scan, MRI (magnetic resonance imaging), ultrasound and other imaging techniques to diagnose diseases and injuries in infants, children and adolescents. Our pediatric radiologists are all fellowship-trained in pediatric radiology.

Supportive care specialists – Our team of supportive care specialists, such as our child life specialists and physical therapists, is here to help your child manage coping with a serious illness.

Child life program

Certified child life specialists help kids cope with a visit to the hospital. They are experts in child development and they partner with doctors, nurses, social workers and other members of your care team to meet the unique needs of your child and your family.

The child life program at Lehigh Valley Reilly Children’s Hospital is the only one in the area where child life specialists help children receiving medical treatment by offering opportunities for stress relief and relaxation, as well as distractions to make procedures easier.

Latest therapies

Medical research helps advance therapies for rare diseases. Because we are a member of COG, we can participate in dozens of clinical trials that explore promising treatments for pediatric cancer. This focus on research helps ensure every patient in our care gets the latest and best treatment.



More cancer services in one place

You can access leading cancer treatments in a kid-friendly space at Children’s Cancer and Multipurpose Infusion Center at Lehigh Valley Reilly Children’s Hospital. The center is located close to our:

- Cancer specialists
- Children’s ER
- Imaging services
- Radiation therapy services
- Pediatric inpatient unit
- J.B. and Kathleen Reilly Children’s Surgery Center

Extensive support

Once cancer touches your life, you are forever changed. Our extensive support-services help your child and your family manage the physical and emotional demands of cancer, from diagnosis to life after treatment.



LVHN Opens Health Center at Macungie

The first part of LVHN's newest medical campus - the Health Center at Macungie - opened for business on Tuesday, Dec. 12, 2023.

The three-story medical office building features HNL Lab Medicine, Children's ExpressCARE and Lehigh Valley Physician Group (LVPG) practices in family medicine, pediatrics, orthopedics and cardiology, as well as outpatient adult rehabilitation and cardiac and vascular diagnostic testing. The HNL site will feature a pediatric-certified phlebotomist and kid-friendly draw rooms.

The Macungie campus is located at the former Weis Market site at 3371 Route 100.

More Services, Close to Home

Lehigh Valley Hospital–Carbon expanded its services in 2023 to bring additional diagnostic and treatment capabilities to Carbon County. The nearly \$12 million upgrade supports high inpatient and outpatient volumes and includes a critical care/step-down unit, which increased the hospital's total inpatient beds to 32.

Other additions included:

- A cardiac rehabilitation center to enhance recovery
- An outpatient laboratory blood-draw station for people needing outpatient tests
- A pulmonary function testing lab that provides valuable information to doctors and clinicians when diagnosing and treating illness

LVH–Carbon also relocated its nearby Breast Health Services practice from Carbon Plaza Mall to the first floor of the health center on the hospital campus.

These expanded services, coupled with the many physicians and clinical specialists who recently joined our team, further help us care for more patients in Carbon County.



New Hospital Coming to Montgomery County

STATE-OF-THE-ART CARE CLOSER FOR DOUGLASS TOWNSHIP RESIDENTS

For people in **Douglass Township, Montgomery County**, in need of expert, compassionate hospital care, the drive is about to get a lot shorter.

Lehigh Valley Health Network is building a new neighborhood hospital and health center that will meet the area's demand for accessible and convenient emergency, outpatient and inpatient care.

Lehigh Valley Hospital–Gilbertsville

This fully licensed and accredited acute care hospital will be staffed by LVHN's board-certified/board-eligible physicians and emergency-educated nurses.

Services to be offered:

- Full-service emergency room
- In-house hospital services: lab, imaging, pharmacy
- Outpatient imaging services: X-ray, ultrasound, CT scan, MRI

By the numbers:

• **22,000** square feet • **11** inpatient beds • Open **24/7**

Other features:

- Smaller footprint makes it a “neighborhood” hospital
- Shorter emergency wait times
- Faster inpatient admission
- Reduced length of stay
- Stabilization and transportation to larger LVHN hospitals for those with surgical needs or acute medical needs

Health Center at Gilbertsville

Located next to the hospital, the health center will house a number of specialties that are unique in Douglass Township.

Services to be offered:

- Lehigh Valley Physician Group (LVPG): primary care, pediatrics, obstetrics and gynecology, orthopedics and sports medicine, cardiology
- Breast Health Services
- Cardiac rehabilitation
- Cardiac and vascular diagnostic testing
- Outpatient adult and pediatric rehabilitation
- HNL Lab Medicine





Hackerman-Patz House

The Hackerman-Patz House at LVH-Cedar Crest is a convenient and affordable “home away from home” that offers you an alternative to an expensive hotel or daily trips to and from your distant home.

Whether your loved one is a patient or you are receiving care yourself, our goal remains the same: to offer you well-appointed, cozy accommodations and a supportive environment that allows you to focus on healing.

We are a member of the Healthcare Hospitality Network, a nationwide network of more than 200 not-for-profit, family lodging facilities that offer warm, caring support to more than a quarter-of-a-million people each year.

House features

Everything in our house is designed to help make a stressful time in your life a little easier. And because you will be staying with other families facing similar circumstances, you will quickly discover you are not alone.

House amenities

- 20 smoke-free, well-appointed private rooms with your choice of one queen bed or two full beds, including eight handicapped-accessible rooms on the first floor
- All rooms include private, upscale bath, safe, TV and mini-fridge
- Kitchenette (Keurig coffee makers, microwaves, refrigerators and vending machine)
- Laundry facilities
- Great room for relaxing and meeting other guests
- Children’s playroom
- Library
- Outdoor patio
- Free Wi-Fi service
- Public computer and printer
- Free, on-site parking
- Use of hospital’s LVHN Fitness facility



Center for Healthcare Education

LVHN Opens Center for Healthcare Education

NEW FACILITY STRENGTHENS LVHN'S EXCEPTIONAL CLINICAL EDUCATION

Lehigh Valley Health Network debuted its **Center for Healthcare Education** at 3900 Sierra Circle, Center Valley. This new building represents the legacy of exceptional clinical education at LVHN and will serve as a premier education and training facility for today's and tomorrow's caregivers.

Consolidating education sites

The center is now home to LVHN's department of education and serves as the hub of education and training programs, consolidating two sites into one 70,000-square-foot location. Features include:

- A state-of-the-art simulation center
- A full-size training operating room
- Plug-and-play capability in all rooms for learners
- Increased classroom size and flexibility
- A reception area, dedicated food services area, dining and event area, auditorium, large computer labs and storage areas

LVHN's department of education supports **1,200** medical, nursing and other students and **340** residents and fellows. The department has provided **190,000** instructional hours of professional development.

Prioritizing learning

LVHN is one of Pennsylvania's largest teaching hospitals, and education remains a leading priority, says Michael Rossi, MD, LVHN's Executive Vice President and Chief Clinical Officer. Dr. Rossi says that education is key to:

- Attracting doctors and clinicians on the leading edge of medical advances
- Providing high-quality care and patient safety
- Growing LVHN's medical education programs to attract the best and brightest
- Facilitating clinical experiences for students in health care professions in the region
- Providing professional development opportunities to clinical staff

One example of the academic programming that will continue in the new facility is LVHN's Nurse Residency Program. Graduate nurses learn from knowledgeable, experienced educators and preceptors and apply their skills in specialized clinical settings across LVHN. It is considered the gold standard among nurse residency programs and will provide newly licensed nurses with a foundation for leadership, critical thinking and evidence-based clinical practice.

The center also allows for the co-creation of programs with education partners, including area school districts, colleges and universities. The new facility adds to or significantly improves many areas of the existing facilities LVHN uses for colleague and student education.



Allyship in Action helps others understand the importance of equality, fairness, acceptance and mutual respect.



Celebrating LGBTQ+ Pride Month at LVHN

Annually celebrated in June, Pride Month is the time when LGBTQ+ community members are recognized for their many contributions to history, society and cultures around the world. Pride Month's roots date to the Stonewall riots of June 1969, which mark the beginning of the LGBTQ+ rights movement. In thinking about this significant piece of LGBTQ+ history, we consider how far the LGBTQ+ community has come and how far we have yet to go.

In any educational presentation and scholarly work regarding the LGBTQ+ community, you will often find information about what the "LGBTQ+" term represents. It is an umbrella term that encompasses people who are lesbian, gay, bisexual, transgender, queer, intersex, asexual and two-spirit. This term is as broad as the community itself.

There have been many iterations, from its beginning of LGB, then LGBT to LGBTQIA and 2SLGBTQIA; now many may use the term "LGBTQ+." This version recognizes inclusiveness, representing all facets of those who identify outside the gender binary and sexual norm. The "+" represents all those identities not represented in the acronym's letters. It is in this spirit of inclusiveness, encompassed in the name itself, that there is one group of people who should be recognized and included: those who are our allies.

For Pride Month 2023, the theme was "Allyship in Action," which recognized, in the spirit of inclusion, those who support the LGBTQ+ community as well as those who want to be an ally and do not know quite how or where to begin.

Allies are some of the most effective and powerful voices for LGBTQ+ individuals; allies stand up for the culturally sensitive and equitable treatment for people different than themselves. Allies show support of LGBTQ+ individuals by helping to end ignorance that can lead to issues and actions that adversely affect the daily lives and livelihoods of LGBTQ+ individuals. Not only do allies help foster safety in the coming-out process, they also help others understand the importance of equality, fairness, acceptance and mutual respect.

2023 PUBLICATIONS

Ranju Gupta, MD

1. Intravascular Large B-Cell Lymphoma Masquerading as Stroke Successfully Treated with R-Hyper-CVAD. Christopher Popiolek¹, Kanchan Gupta,² Mallorie L Huff,¹ Ranju Gupta¹ Leuk Res Rep. 2023 Nov 27:21:100401. doi: 0.1016/j.lrr.2023.100401. eCollection 2024. PMID: 38124760 PMID: PMC10731217

Timothy Johnson, DO

1. Screening Success: A Review Of Outcomes From Lehigh Valley Health Network's Multi-Disciplinary Lung Cancer Screening Program. Timothy R. Johnson DO,¹ Andrea Dally CRNP,² Kenneth Cavorsi MD,³ Richard Chang MD,⁴ Dennis Sopka MD,⁵ C. Gerard Petersen MD,² Frank Sperrazza MD,⁶ Dylan Soller DO,² and Eliot L. Friedman MD¹
2. Johnson RT, Wright J, Grau J, Khalil M (2023) An Unexpected Finding: High-Grade Neuroendocrine Tumor in a Patient with Known Familial Adenomatous Polyposis (FAP) Ann Case Report 8 1493 <https://doi.org/10.29011/2574-7754.101493>

Hariharasudan Mani, MD

1. Mani H, Hossain A, Lee E, et al. (Feb. 14, 2024) A Rare Case of Duodenal Adenocarcinoma With Brain Metastasis. Cureus 16(2): e54202. doi:10.7759/cureus.54202
2. Schroeder, K. E., Acharya, L., Mani, H., Muhammad Furqan, & Sieren, J. C. (2023). Radiomic biomarkers from chest computed tomography are assistive in immunotherapy response prediction for non-small cell lung cancer. Translational Lung Cancer Research, 12(5), 1023-1033. <https://doi.org/10.21037/tlcr-22-763>

Suresh Nair, MD

1. Kinney RE, Nair S, Kim CH, Thomas MB, DelaTorre M. Immunotherapy May Improve Tumor Sensitivity to Palliative Chemotherapy in Platinum Resistant Ovarian Cancer. Oncologist. 2023 Apr 7:oyad079. doi: 10.1093/oncolo/oyad079. Epub ahead of print. PMID: 37027520
2. Coleman JA, Yip W, Wong NC, Sjoberg DD, Bochner BH, Dalbagni G, Donat SM, Herr HW, Cha EK, Donahue TF, Pietzak EJ, Hakimi AA, Kim K, Al-Ahmadie HA, Vargas HA, Alvim RG, Ghafoor S, Benfante NE, Meraney AM, Shichman SJ, Kamradt JM, Nair SG, Baccala AA Jr, Palyca P, Lash BW, Rizvi MA, Swanson SK, Muina AF, Apolo AB, Iyer G, Rosenberg JE, Teo MY, Bajorin DF. Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma. J Clin Oncol. 2023 Mar 10;41(8):1618-1625. doi: 10.1200/JCO.22.00763. Epub 2023 Jan 5. PMID: 36603175; PMID: PMC10043554
3. Tomlins SA, Khazanov NA, Bulen BJ, Hovelson DH, Shreve MJ, Lamb LE, Matrana MR, Burkard ME, Yang ES, Edenfield WJ, Dees EC, Onitilo AA, Thompson M, Buchschacher GL Jr, Miller AM, Menter A, Parsons B, Wassenaar T, Hwang LC, Suga JM, Siegel R, Irvin W Jr, Nair S, Slim JN, Misleh J, Khatri J, Masters G, Thomas S, Safa M, Anderson DM, Kwiatkowski K, Mitchell K, Hu-Seliger T, Drewery S, Fischer A, Plouffe K, Czuprenski E, Hipp J, Reeder T, Vakil H, Johnson DB, Rhodes DR. Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit. Commun Med (Lond). 2023 Feb 7;3(1):14. doi: 10.1038/s43856-023-00243-7. PMID: 36750617; PMID: PMC9905474
4. Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, Yamaguchi TN, Daras M, Cloughesy TF, Colman H, Kumthekar PU, Chen CC, Aiken R, Groves MD, Ong SS, Ramakrishna R, Vogelbaum MA, Khagi S, Kaley T, Melear JM, Peereboom DM, Rodriguez A, Yankelevich M, Nair SG, Puduvalli VK, Aldape K, Gao A, López-Janeiro Á, de Andrea CE, Alonso MM, Boutros P, Robbins J, Mason WP, Sonabend AM, Stupp R, Fueyo J, Gomez-Manzano C, Lang FF, Zadeh G. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nat Med. 2023 May 15. doi: 10.1038/s41591-023-02347-y. Epub ahead of print. PMID: 37188783

- Bulen BJ, Khazanov NA, Hovelson DH, Lamb LE, Matrana M, Burkard ME, Yang ES, Edenfield WJ, Claire Dees E, Onitilo AA, Buchschacher GL, Miller AM, Parsons BM, Wassenaar TR, Suga JM, Siegel RD, Irvin W, Nair S, Slim JN, Misleh J, Khatri J, Masters GA, Thomas S, Safa MM, Anderson DM, Mowers J, Dusenbery AC, Drewery S, Plouffe K, Reeder T, Vakil H, Patrias L, Falzetta A, Hamilton R, Kwiatkowski K, Johnson DB, Rhodes DR, Tomlins SA. Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit. *Cancer Res Commun*. 2023 Jul 25;3(7):1335-1349. doi: 10.1158/2767-9764.CRC-23-0036. PMID: 37497337; PMCID: PMC10367935

Jacqueline Oxenberg, DO

- Ruffino A, Madera J, Dearborn M, Frank K, Oxenberg J. The Efficacy of Axillary Reverse Mapping for the Prevention of Lymphedema. *The American Surgeon*. 2024; 90(2):199-206
- Lushefski K, Wolf M, Dove J, Fluck M, Oxenberg J. The Correlation of Thyroid Hormone Levels and Anti-Thyroidal Drugs on Thyroid Size, Weight, and Ease of Surgical Dissection for Thyroidectomy for Graves' Disease. *The American Surgeon*. 2024;90(1):15-22
- Lushefski K, Gallagher A, Wolf M, Oxenberg J. Thyroid Hormone Levels and Anti-Thyroidal Drugs Do Not Correlate with Ease of Surgical Dissection or Morbidity for Thyroidectomy for Graves' Disease. Abstract published in *JACS* 236(5):pS29, May 2023.
- Burger M, Haggerty J, Wang S, Oxenberg J. Deep Margins for Melanoma: How Deep is Deep Enough? *The American Surgeon*. Dec 2023;89(12):5297-5303
- Marjoncu D, Carmichael J, Andrick B, Oxenberg J. Assessment of Hold-Times for Oral Chemotherapy Agents with High Bleed Risks Surrounding Surgical Procedures. *Journal of Hematology Oncology Pharmacy*. June 2023, Vol 13 (3) p140
- Jordan R, Rebielak M, Johnson K, Fluck M, Oxenberg J. Improved Overall Well-Being After Breast Conserving Therapy Using Three-Dimensional Bioabsorbable Markers and Tissue Rearrangement, a Single Institution's Preliminary Experience. *The American Surgeon*. May 2023;89(5):2111-2114

Dennis Sopka, MD

- Andreas Rimner, Zachary R. Moore, Stephanie Lobaugh, Alexander Geyer, Daphna Y. Gelblum, Raja-Elie E. Abdulnour, Annemarie F. Shepherd, Narek Shaverdian, Abraham J. Wu, John Cuaron, Jamie E. Chaft, Marjorie G. Zauderer, Juliana Eng, Gregory J. Riely, Charles M. Rudin, Nicholas Vander Els, Mohit Chawla, Megan McCune, Henry Li, David R. Jones, Dennis M. Sopka, Charles B. Simone, Raymond Mak, Gerald L. Weinhouse, Zhongxing Liao, Daniel R. Gomez, Zhigang Zhang, Paul K. Paik, Randomized, phase 2, placebo-controlled trial of nintedanib for the treatment of radiation pneumonitis, *International Journal of Radiation Oncology*Biophysics*, 2023, ISSN 0360-3016, <https://doi.org/10.1016/j.ijrobp.2023.02.030>. (<https://www.sciencedirect.com/science/article/pii/S0360301623001773>)

Amir Toor, MD

- Systematic Evaluation of Donor-KIR/Recipient-HLA Interactions in HLA-matched Hematopoietic Cell Transplantation for AML.**
Fein JA, Shouval R, Krieger E, Spellman SR, Wang T, Baldauf H, Fleischhauer K, Kröger N, Horowitz MM, Maiers M, Miller JS, Mohty M, Nagler A, Weisdorf DJ, Malmberg KJ, Toor AA, Schetelig J, Romee R, Koreth J. *Blood Adv*. 2023 Dec 5:bloodadvances.2023011622. doi: 10.1182/bloodadvances.2023011622. Online ahead of print. PMID: 38052043
- Intravenous Vitamin C Supplementation in Allogeneic Hematopoietic Cell Transplant Recipients: Salutary Impact on Clinical Outcomes.**
Toor A, Simmons G, Sabo R, Aziz M, Martin E, Bernard R, Sriparna M, McIntire C, Kreiger E, Brophy D, Natarajan R, Fowler A, Roberts C. *Res Sq*. 2023 Nov 10:rs.3.rs-3538792. doi: 10.21203/rs.3.rs-3538792/v1. Preprint. PMID: 37986783
Free PMC article.

3. **Allogeneic haematopoietic cell transplants as dynamical systems: influence of early-term immune milieu on long-term T-cell recovery.**
Zelikson V, Sabo R, Serrano M, Aqeel Y, Ward S, Al Juhaishi T, Aziz M, Krieger E, Simmons G, Roberts C, Reed J, Buck G, Toor A.
Clin Transl Immunology. 2023 Jul 13;12(7):e1458.
doi: 10.1002/cti2.1458. eCollection 2023.
PMID: 37457614
Free PMC article.
4. **SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study.**
Hill JA, Martens MJ, Young JH, Bhavsar K, Kou J, Chen M, Lee LW, Baluch A, Dhodapkar MV, Nakamura R, Peyton K, Shahid Z, Armistead P, Westervelt P, McCarty J, McGuirk J, Hamadani M, DeWolf S, Hosszu K, Sharon E, Spahn A, Toor AA, Waldvogel S, Greenberger LM, Auletta JJ, Horowitz MM, Riches ML, Perales MA.
EClinicalMedicine. 2023 May;59:101983.
doi: 10.1016/j.eclinm.2023.101983. Epub 2023 Apr 27.
PMID: 37128256
Free PMC article.
5. **Cell-free next-generation sequencing impacts diagnosis and antimicrobial therapy in immunocompromised hosts: A retrospective study.**
Vissicelli NC, Morales MK, Kolipakkam B, Bryson A, Sabo RT, Toor AA.
Transpl Infect Dis. 2023 Feb;25(1):e13954. doi: 10.1111/tid.13954. Epub 2023 Jan 11.
PMID: 36632004
6. **DNA Methylation Changes in Autologous Hematopoietic Stem Cell Transplant Patients.**
Mohanraj L, Wolf H, Silvey S, Liu J, Toor A, Swift-Scanlan T.
Biol Res Nurs. 2023 Apr;25(2):310-325.
doi: 10.1177/10998004221135628. Epub 2022 Nov 2.
PMID: 36321693
7. **Engraftment syndrome after allogeneic stem cell transplantation: a systematic review and meta-analysis.**
ElGohary G, Toor AA, Gergis U.
Bone Marrow Transplant. 2023 Jan;58(1):1-9.
doi: 10.1038/s41409-022-01849-6. Epub 2022 Oct 25.
PMID: 36284212
Review.
8. **DNA Methylation Research in Autologous Hematopoietic Stem Cell Transplant Population.**
Mohanraj L, Lapato DM, Toor A, Swift-Scanlan T.
Biol Res Nurs. 2023 Apr;25(2):220-226.
doi: 10.1177/10998004221132251. Epub 2022 Oct 14.
PMID: 36242509
9. **Increased Donor Inhibitory KIR Are Associated with Reduced GVHD and Improved Survival Following HLA Matched Unrelated Donor HCT in Pediatric Acute Leukemia.**
Elizabeth Krieger, Rehan Qayyum, Amir Toor
medRxiv 2023.12.14.23299955;
doi: <https://doi.org/10.1101/2023.12.14.23299955>

Lehigh Valley Topper Cancer Institute Locations

Lehigh Valley Topper Cancer Institute offers a range of services in convenient, patient-focused locations.

Lehigh Valley Physician Group (LVPG) practices provide services in Allentown, Bethlehem, East Stroudsburg, Easton, Hazleton, Lehigh, Pottsville and Scranton.

CANCER CENTERS

- Cancer Center at LVH–Carbon
- Cancer Center at LVH–Hazleton
- Cancer Center at LVH–Hecktown Oaks
- Dale and Frances Hughes Cancer Center at Lehigh Valley Hospital–Pocono
- John and Dorothy Morgan Cancer Center at Lehigh Valley Hospital–Cedar Crest
- LVHN Cancer Center at Lehigh Valley Hospital–Muhlenberg
- LVHN Cancer Center–Schuylkill
- LVPG Radiation Oncology–Morgan Highway

BREAST HEALTH SERVICES

- Health Center at Bangor
- Health Center at Bartonsville
- Health Center at Bath
- Health Center at Bethlehem Township
- Health Center at Moselem Springs
- Health Center at Trexlertown
- Health & Wellness Center at Hazleton
- Lehigh Valley Health Network–Steamtown
- Lehigh Valley Hospital–17th Street
- Lehigh Valley Hospital–Carbon
- Lehigh Valley Hospital–Cedar Crest
- Lehigh Valley Hospital–Hecktown Oaks
- Lehigh Valley Hospital–Muhlenberg
- Lehigh Valley Hospital–Pocono
- Lehigh Valley Hospital–Schuylkill
- LVHN Imaging Center
- Mobile mammography coach



Lehigh Valley Health Network Cancer Program Affiliations

- American College of Surgeons' Commission on Cancer Accreditation (ACoS CoC)
- Member, Memorial Sloan Kettering Cancer Alliance
- Member, Michigan Cancer Research Consortium National Community Oncology Research Program (NCORP)
- Rapid Cancer Reporting System (RCRS)
- American College of Radiology (ACR) Radiation Oncology Practice Accreditation since 2012
- American College of Radiology (ACR) Breast Health Services Accreditation
- American College of Radiology (ACR) Breast Imaging Center of Excellence Designation (BICOE)
- American College of Radiology (ACR) Lung Cancer Screening Center
- National Accreditation Program for Breast Centers (NAPBC) Breast Health Services Accreditation
- National Quality Measures for Breast Centers (NQMBC) Certified Quality Breast Center of Excellence – Breast Health Services
- Quality Oncology Practice Initiative (QOPI) LVPG Hematology Oncology – certified since 2011
- U.S. News & World Report 2014-2015 High Performer – Cancer
- NCI Community Cancer Center Program Selected (NCCCP), April 2010-June 2014 (one of 21)
- National Committee Quality Assurance (NCQA) Patient-Centered Specialty Practice Level 2 Recognition – LVPG Hematology Oncology, March 20, 2014-March 2017

